

# COVID-19 vaccine candidates

January 8, 2021



Disclaimer: The information contained in this document is intended for informational purposes only and is in no way intended to be a substitute for or in any manner to be construed as medical or clinical advice for any patient in your care. The authors, editors, reviewers, contributors and publishers cannot be held responsible for the accuracy or continued accuracy of the information or for any errors or omissions in the document or for any consequences in the form of liability, loss, injury, or damage incurred as a result of the use and application of any of the information, either directly or indirectly. All medical and clinical decisions regarding any patient's care are the responsibility of the patient's physician.

The information contained throughout this document is confidential and proprietary in nature to Vizient, Inc. Use or distribution of this information without Vizient's express written permission is prohibited.

## Table of contents

|  |    |
|--|----|
| Summary of changes since last publication (update: January 8, 2021)                          | 4  |
| Late-stage COVID-19 vaccine candidates in United States side-by-side comparison <sup>a</sup> | 5  |
| Evidence summary: COVID-19 vaccines  | 15 |
| Introduction   | 15 |
| Side-by-side document  | 16 |
| Efficacy and safety considerations   | 16 |
| Late-stage vaccine candidates  | 17 |
| mRNA-1273  | 17 |
| Efficacy   | 18 |
| Safety   | 20 |
| BNT 162b2  | 21 |
| Efficacy and safety: Phase 1   | 22 |
| Phase 2/3 Study  | 22 |
| mRNA vaccines – Anaphylaxis reactions  | 25 |
| AZD1222  | 26 |
| Efficacy   | 27 |
| Safety   | 27 |
| JNJ-78436735   | 28 |
| Efficacy and safety: Phase 1/2a  | 28 |
| Phase 3  | 28 |
| NVX-CoV2373  | 29 |
| Efficacy and safety: Phase 1   | 29 |
| Phase 3  | 29 |
| References   | 30 |
| Appendix A – mRNA-1273 trials  | 33 |
| Appendix B – BNT162b2 trials   | 35 |
| Appendix C – AZD1222 trials  | 37 |
| Appendix D – JNJ-78436735 trials   | 45 |
| Appendix E – NVX-CoV2373 trials  | 48 |

## Summary of changes since last publication (update: January 8, 2021)

- Added information on Moderna vaccine found in the **EUA Fact Sheet** and **full prescribing information** for vaccination providers (vaccine table)
- Added CDC information regarding appropriate needle length and gauge (vaccine table)
- Added information from the **CDC** on the recommended 4-day grace period for administration of the second dose of the vaccine (vaccine table)
- Added information from the **CDC** on the vaccination of persons with underlying medical conditions (vaccine table)
- Added information from the **CDC** on co-administration of COVID-19 vaccines with other vaccines (vaccine table)
- Added updated ACIP interim vaccine allocation recommendations (white paper)
- Added information from the **CDC** on the management of anaphylaxis, including inactive ingredients of vaccines (white paper)
- Added information about AZD1222 international approval (white paper)
- Added information about NVX-CoV237 initiating phase 3 trials in US and Mexico (white paper)

## Late-stage COVID-19 vaccine candidates in United States side-by-side comparison<sup>a</sup>

|   | Vaccine candidates   |   |   |  |   |
|---|--|---|---|--|---|
|   | mRNA vaccines  |   | Replication-defective vectored vaccines   |  | Protein subunit   |
|   | mRNA-1273 (Moderna)  | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)   | NVX-CoV2373 (Novavax)   |
| <b>Manufacturer</b>                           | Moderna/NIAID  | Pfizer Inc/BioNTech SE  | AstraZeneca   | Janssen  | Novavax   |
| <b>Vaccine market experience</b>              | No   | Yes (Pfizer)  | Yes   | Yes  | No  |
| <b>FDA status (if authorized, indication)</b> | EUA – For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥ 18 y  | EUA – For active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged ≥ 16 y | TBA   | TBA  | TBA   |
| <b>Vaccine platform technology</b>            | LNP-encapsulated, nucleoside-modified mRNA vaccine   | LNP formulated, nucleoside-modified mRNA vaccine  | Recombinant, replication-defective simian adenovirus vector   | Recombinant, replication-defective adenovirus type 26 vector leveraging AdVac technology | Recombinant nanoparticle vaccine technology, leveraging Sf9/BV insect cell platform and Matrix-M™ adjuvant technology   |
| <b>Licensed platform</b>                      | EUA approval of Pfizer and Moderna vaccines  |   | No <sup>b</sup>   | Yes (EU Ebola)   | Yes   |
| <b>Platform differentiators</b>               | <p>Potential advantages:</p> <ul style="list-style-type: none"> <li>Safety – mRNA is non-infectious and non-integrating. There is no potential risk of infection or insertional mutagenesis. Additionally, mRNA is rapidly degraded by normal cellular processes.</li> <li>Scalable production - engineered production facilitates large-scale vaccine production.</li> <li>Potency - capable of generating humoral and cellular immunity.</li> <li>Efficacy - structural modifications during engineering improves stability and translation efficacy of mRNA.</li> </ul> <p>Potential disadvantages:</p> <ul style="list-style-type: none"> <li>Lack of commercial vaccine precedent in humans</li> <li>Local and systemic inflammatory responses</li> <li>Biodistribution and persistence of the induced antigen expression</li> <li>Possible development of autoreactive antibodies</li> <li>Toxic effects of any non-native nucleotides and delivery system components</li> </ul> |   | <p>Potential advantages:</p> <ul style="list-style-type: none"> <li>Stability at refrigerated temperatures</li> <li>Experience with platform</li> </ul> <p>Potential disadvantages:</p> <ul style="list-style-type: none"> <li>No commercial vaccine precedent in humans</li> </ul> |  | <p>Potential advantages:</p> <ul style="list-style-type: none"> <li>Safety – non-infectious, non-integrating</li> <li>Scalable production – engineered production facilitates large-scale vaccine production</li> <li>Potency – capable of generating humoral and cellular immunity</li> <li>Adjuvanted –provides enhanced immune response, allowing for vaccine dose-sparing effect</li> </ul> <p>Potential disadvantages:</p> <ul style="list-style-type: none"> <li>Local and systemic inflammatory responses</li> </ul> |

|   | Vaccine candidates   |   |   |   |  |
|---|--|---|---|---|--|
|   | mRNA vaccines  |   | Replication-defective vectored vaccines   |   | Protein subunit  |
|   | mRNA-1273 (Moderna)  | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)  | NVX-CoV2373 (Novavax)  |
| <b>Annualized manufacturing capacity goal</b> | Forecast up to 600 million doses in 2021   | Up to 50 million doses worldwide by the end of 2020 and ~1.3 billion doses by the end of 2021 | Up to 2 billion doses by the end of 2021  | Up to 1 billion doses by end of 2021 (J&J owned facilities) | Up to 2 billion doses by mid-2021  |
| <b>Targeted SARS-CoV-2 antigen</b>            | Full-length, prefusion stabilized SARS-CoV-2 spike protein   |   | SARS-CoV-2 spike protein  | Full-length, stabilized SARS-CoV-2 spike protein            | Full-length, prefusion stabilized SARS-CoV-2 spike protein   |
| <b>Pharmacology</b>                           | mRNA encoding for the SARS-CoV-2 spike glycoprotein is delivered to cells in a lipid capsule; using this mRNA, cells manufacture the spike protein (antigen), which stimulates the body's immune response and production of antibodies against SARS-CoV-2. |   | DNA sequence for SARS-CoV-2 spike glycoprotein (antigen) is encoded into a human or non-human adenovirus. Upon delivery to the host cell, host cells manufacture the spike protein (antigen), which stimulates the body's immune response. AZD1222 uses a simian adenovirus and JNJ-78436735 uses a human adenovirus with a low prevalence in humans. Due to genetic alterations, adenovirus vectors are unable to replicate (replication-defective) once in the host cell. |   | Genetic sequence encoding the antigen (spike protein) is cloned into baculovirus and inserted into Sf9 insect cells, where the antigen is produced and subsequently isolated/extracted. Matrix-M adjuvant boosts immune response and enables vaccine dose-sparing by stimulating entry of antigen-presenting cells into the injection site and enhancing B- and T-cell responses |
| <b>Immunology</b>                             |  |   |   |   |  |
| Humoral                                       | Development of binding and neutralizing antibodies against SARS-CoV-2 spike protein  |   |   |   |  |
| Cellular (CD4+)                               | Th1-biased   | Th1-biased  | Th1-biased  | Th1-biased  | Th1-biased   |
| Cellular (CD8+)                               | √  | √   | Unknown   | √ (varies by age and dose)                                  | √  |
| <b>Manufacturing process</b>                  | Genetically engineered   |   |   |   |  |
| <b>Distribution</b>                           |  |   |   |   |  |
| Number of shipped components                  | 2  | 2   | NR  | NR  | NR   |

|  | Vaccine candidates  |   |  |  |                       |
|--|---|---|--|--|-----------------------|
|  | mRNA vaccines   |   | Replication-defective vectored vaccines                    |  | Protein subunit       |
|  | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)                                      | JNJ-78436735 (J&J)   | NVX-CoV2373 (Novavax) |
| Vaccine  | <ul style="list-style-type: none"> <li>Moderna ships to central distributor at -20° C</li> <li>Central distributor ships to States and Jurisdictions</li> </ul> | <ul style="list-style-type: none"> <li>Pfizer ships directly to administration sites or to hubs (state dependent)</li> <li>Shipped in temperature-controlled thermal shipper, which utilizes dry ice to maintain ULT</li> <li>Note: Thermal shipper keeps ULT up to 10 d if stored at 15°C to 25°C without opening (allows for global transit)</li> </ul>   | NR   | NR   | NR                    |
| <b>Ancillary supply kits</b>   | From kitting facility to central distributor to States and Jurisdictions, at RT   | Direct to site from kitting facility, at RT   | NR   | NR   | NR                    |
| <b>How supplied</b>  |   |   |  |  |                       |
| Multidose vial   | 10 to 11 doses/vial <sup>c</sup><br>Vial size: 5 mL<br>(Does not contain latex)   | 5 to 7 doses/vial <sup>c</sup><br>Vial size: 2 mL<br>(Does not contain latex)   | 10 doses/vial (C.Dube, oral communication, September 2020) | 5 doses/vial (ACIP meeting, October 2020)  | NR                    |
| <b>Anticipated commercial vaccine storage conditions – unopened vial (investigational conditions may differ)</b> |   |   |  |  |                       |
| Frozen or ultra-cold   | Store at -20°C±5°C  | <b>Two options for storage:</b> <ul style="list-style-type: none"> <li>Transfer to a ULT freezer (-70°C±10°C) immediately upon receipt (shelf-life: up to 6 mo)</li> <li>If a ULT freezer is not available, the thermal shipper may be used as temporary storage for up to 30 d, provided instructions in the re-icing guidelines (packed in the original thermal container) are carefully</li> </ul> | Not applicable   | <ul style="list-style-type: none"> <li>Stored at -20° C</li> <li>Stable for 2 y</li> </ul> | Not applicable        |

|                            | Vaccine candidates  |   |   |                    |                           |
|----------------------------|---|---|---|--------------------|---------------------------|
|                            | mRNA vaccines   |   | Replication-defective vectored vaccines             |                    | Protein subunit           |
|                            | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)                               | JNJ-78436735 (J&J) | NVX-CoV2373 (Novavax)     |
|                            |   | <p>followed</p> <p><b>Highlights for using the thermal shipper as temporary storage:</b></p> <p><i>See Pfizer Re-icing Guidelines provided in thermal container</i></p> <ul style="list-style-type: none"> <li>• Upon receipt and after opening, replenish with dry ice (filled to top of container) within 24 h</li> <li>• Store at 15-25°C</li> <li>• Open no more than 2 times a day, for no more than 3 min at a time; assuming this guidance is followed, the shipper should be re-iced every 5 d. This will allow for up to 30 d of storage.</li> <li>• After storage for 30 d in the thermal shipper, the vaccine can be transferred to a refrigerator (2-8°C) for an additional 5 d, for a total of up to 35 d of storage.</li> </ul> |   |                    |                           |
| Refrigeration (2-8°C)      | Stable for 30 d   | Undiluted vial: 5 d   | Until date printed on packaging (at least 6 months) | Stable for 3 mo    | Store under refrigeration |
| Room temperature           | Stable for 12 h   | Undiluted vial: 2 h   | NR  | NR                 | NR                        |
| <b>BU after vial entry</b> | <ul style="list-style-type: none"> <li>• 6 h, stored between 2-25°C</li> <li>• USP Compounding Expert Committee added <b>operational considerations</b> for preparing conventionally manufactured COVID-19 vaccines after FDA issued EUA</li> </ul> |   | 4 h (C Dube, written communication, November 2020)  | 6 h                | NR                        |



|                                       | Vaccine candidates  |   |   |   |  |
|---------------------------------------|---|---|---|---|--|
|                                       | mRNA vaccines   |   | Replication-defective vectored vaccines   |   | Protein subunit                                  |
|                                       | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)  | NVX-CoV2373 (Novavax)                            |
| <b>Dosage and administration</b>      |   |   |   |   |  |
| Dose                                  | 100 mcg/0.5 mL  | 30 mcg/0.3 mL   | 5x10 <sup>10</sup> vp dose or 3.5-6.5 x 10 <sup>10</sup> vp dose (phase 3)      | 5x10 <sup>10</sup> vp dose  | 5 mcg protein antigen + 50 mcg Matrix-M adjuvant |
| Number of doses                       | 2-dose series (28 d between doses) <ul style="list-style-type: none"> <li>Second doses administered within 4 d earlier than recommended are considered valid (e.g., Moderna – days 24-27; Pfizer – days 17-20) (per CDC)</li> <li>There is no maximum interval between the first and second dose – there is no need to restart a vaccine series if second dose is administered later than recommended.</li> <li>Both doses are necessary for protection; efficacy of a single dose has not been evaluated.<sup>d</sup></li> </ul> | 2-dose series (21 d between doses)  | 2-dose series (28 d between doses) (C.Dube, oral communication, September 2020) | 1 dose (ENSEMBLE trial) or 2 dose-series (57 d between doses; ENSEMBLE 2 trial) | 2-dose series (21 d between doses)               |
| Co-administration with other vaccines | <ul style="list-style-type: none"> <li>Due to insufficient evidence, administer vaccine series alone, with a minimum interval of 14 d before or after administration with any other vaccine.</li> <li>If inadvertently administered within 14 d of another vaccine, doses do not need to be repeated for either vaccine.</li> </ul>   |   | NR  | NR  | NR   |
| Administration route                  | Intramuscular   | Intramuscular   | Intramuscular   | Intramuscular   | Intramuscular                                    |
| Dilution required                     | No  | Yes   | No  | No  | No   |
| Preparation                           | <i>Full details on preparation can be found in the <b>Fact Sheet for HCP</b>.</i> <ul style="list-style-type: none"> <li>Frozen vials must be thawed prior to administration – either under refrigeration (2 h and 30 min) or at room temperature (≤25°C for 1 h).</li> <li>After thawing, do not refreeze</li> </ul>   | <i>Full details on preparation can be found in the <b>Fact Sheet for HCP</b>.</i> <ul style="list-style-type: none"> <li>Frozen vials must be thawed to room temperature prior to dilution – either under refrigeration (up to 3 h) or at room temperature (≤25°C; up to 30 min).</li> <li>Dilute in original vial with 1.8 mL of sterile 0.9% Sodium Chloride</li> </ul> | Not applicable  | Not applicable  | Not applicable                                   |

|  | Vaccine candidates   |   |   |                    |                       |
|--|--|---|---|--------------------|-----------------------|
|  | mRNA vaccines  |   | Replication-defective vectored vaccines |                    | Protein subunit       |
|  | mRNA-1273 (Moderna)  | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)                   | JNJ-78436735 (J&J) | NVX-CoV2373 (Novavax) |
|  | <ul style="list-style-type: none"> <li>Swirl vial gently after thawing and between each withdrawal</li> <li>Record date and time of first use on vial label.</li> </ul>  | <ul style="list-style-type: none"> <li>Injection, USP (Do not use bacteriostatic 0.9% Sodium Chloride Injection).</li> <li>Record the date and time of dilution on the vaccine vial label.</li> </ul> |   |                    |                       |
| Needle selection                                     | <ul style="list-style-type: none"> <li>Choice of appropriate needle length and gauge is directed by patient age, gender, weight, injection site and route of administration. Improper selection may inhibit vaccine reaching targeted tissue and possibly efficacy. See <b>CDC recommendations</b> for guidance.</li> <li>The CDC has <b>indicated</b> for both the Pfizer and Moderna vaccines that “changing needles between drawing vaccine from a vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated”</li> </ul> |   |   |                    |                       |
| Considerations in specific populations               |  |   |   |                    |                       |
| Current or prior history of SARS-CoV-2 infection     | <ul style="list-style-type: none"> <li>Current infection - vaccination should be deferred until the person has recovered from acute illness and criteria have been met for isolation discontinuation.</li> <li>Past infection - there is no recommended minimum interval between infection and vaccination; evidence suggests re-infection is uncommon within 90 d.</li> </ul>   |   | NR                                      | NR                 | NR                    |
| History of passive antibody therapy                  | <ul style="list-style-type: none"> <li>Vaccination should be deferred for at least 90 d in those that have received monoclonal antibodies or convalescent plasma as a part of COVID-19 therapy. Recommendation applies to first and second doses.</li> <li>There is no recommended minimum interval between COVID-19 vaccination and other antibody therapies.</li> </ul>  |   | NR                                      | NR                 | NR                    |
| Persons with immunocompromise or autoimmune disorder | <ul style="list-style-type: none"> <li>Immunocompromising and autoimmune conditions – Limited data available, but these individuals may receive the vaccine if no contraindications.</li> <li>Persons with stable HIV were enrolled in trials</li> </ul>   |   | NR                                      | NR                 | NR                    |
| Pregnancy or lactation                               | <ul style="list-style-type: none"> <li>Pregnancy – Limited data, but experts believe mRNA vaccines are unlikely to pose a risk. Individual benefit vs. risk assessment should guide vaccination.</li> <li>Lactation – mRNA vaccines are not thought to be a risk to a breastfeeding infant. Lactation is not a contraindication to vaccination.</li> </ul>   |   | NR                                      | NR                 | NR                    |

|                                    | Vaccine candidates  |   |   |  |   |
|------------------------------------|---|---|---|--|---|
|                                    | mRNA vaccines   |   | Replication-defective vectored vaccines   |  | Protein subunit   |
|                                    | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)   | NVX-CoV2373 (Novavax)   |
| <b>Safety considerations</b>       |   |   |   |  |   |
| Contraindications                  | <ul style="list-style-type: none"> <li>Severe allergic reaction (e.g. anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components.</li> <li>Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol).<sup>e</sup></li> <li>Immediate allergic reaction of any severity to polysorbate.<sup>e</sup></li> </ul>  |   | NR  | NR   | NR  |
| Precautions                        | <ul style="list-style-type: none"> <li>Balance risk vs. benefit in persons with a history of any immediate allergic reaction to any other vaccine or injectable therapy.</li> <li>Persons with a history of an immediate allergic reaction of any severity to a vaccine or injectable therapy and persons with a history of anaphylaxis due to any cause, observe for 30 min. All others, observe for 15 min.</li> </ul>  |   | NR  | NR   | NR  |
| Adverse effects (vaccine specific) | <p>Phase 3 (11/11 dataset, n = 30,350)<sup>f</sup></p> <ul style="list-style-type: none"> <li>FDA analysis – most common solicited ADEs: injection site pain (91.6%), fatigue (68.5%), headache (63%), muscle pain (59.6%), joint pain (44.8%), chills (43.4%)</li> <li>Local solicited ADEs – most common was injection site pain, comparable incidence after dose 1 and 2 (83.7% and 88.4%, respectively). Most local ADEs were grade 1 or 2; grade 3 events were more common after dose 2, and the most</li> </ul> | <p>Phase 2/3 (reactogenicity subset, n = 8,183)</p> <ul style="list-style-type: none"> <li>FDA analysis - most common solicited ADEs: injection site pain (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%)</li> <li>Local solicited ADEs – most common was injection site pain, reported less frequently in recipients aged ≥ 55 y (71% after dose 1, 66% after dose 2) than those aged &lt; 55 y (83% and 78%, respectively). Pain was mostly mild to</li> </ul> | <p>ADEs in phase 1/2 trial were limited to non-serious (pain, tenderness, headache, fatigue) and had decreased frequency in patients treated with paracetamol.</p> <p>In the phase 2 component of 2/3 UK trial the most common local ADEs were pain and tenderness at the injection site with the most common systemic ADEs of fatigue, headache, feverishness, and myalgia. Decreased reactogenicity was observed in older adults.</p> <p>In 4 phase 3 trials,</p> | <ul style="list-style-type: none"> <li>Local and systemic reactions reported in pre-publication manuscript included, but were not limited to: injection site pain, headache, fatigue, and myalgia.<sup>s</sup></li> <li>Unsolicited ADEs were reported in both age groups studied and included 1 necessitating drug withdrawal (pyrexia).</li> </ul> | <ul style="list-style-type: none"> <li>Some local and systemic reactions reported in phase 1 trial (placebo-controlled)</li> <li>Absent or mild in majority of patients after both first and second vaccinations.</li> <li>No serious ADEs were noted.</li> </ul> |

|  | Vaccine candidates  |  |   |   |  |
|--|---|--|---|---|--|
|  | mRNA vaccines   |  | Replication-defective vectored vaccines   |   | Protein subunit  |
|  | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)  | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)  | NVX-CoV2373 (Novavax)  |
|  | <p>common grade 3 was injection site pain (4.1% dose 2)</p> <ul style="list-style-type: none"> <li>Systemic solicited ADEs – most common were fatigue and headache, incidence and severity increased after dose 2 (fatigue: 37.2% (dose 1), 65.2% (dose 2); headache: 32.7% (dose 1) and 58.6% (dose 2))</li> </ul> <p>Most common grade 3 ADEs after dose 2 were fatigue (9.7%), myalgia (8.8%), headache (4.5%), and arthralgia (5.2%).</p> | <p>moderate and resolved within 1-2 d.</p> <ul style="list-style-type: none"> <li>Systemic solicited ADEs – most common were fatigue and headache (59% and 52% in recipients aged &lt; 55 y and 51% and 39% in recipients aged ≥ 55 y). Frequency of systemic ADEs was higher in aged &lt; 55 y and within each age cohort, severity was higher after dose 2, except for vomiting and diarrhea.</li> </ul> | <p>serious adverse events occurred in 79 vaccine recipients. One case of transverse myelitis was reported following a booster dose and was thought to be possibly related to vaccination. An unmasked patient experienced a high fever (&gt; 40°C). One additional case of transverse myelitis was determined likely unrelated to vaccine administration.</p> |   |  |
| <b>Special populations in phase 3 trials</b> |   |  |   |   |  |
| Geriatrics                                   | <p>Demographics of per-protocol efficacy population (11/11) in EUA submission (n = 27,817)<sup>f</sup></p> <ul style="list-style-type: none"> <li>Median age: 53 y (range 18-95 y)</li> <li>≥ 65 y: 25.3%</li> </ul>  | <p>Demographics of evaluable efficacy population in EUA submission (n = 40,277):</p> <ul style="list-style-type: none"> <li>Median age: 51 y (range: 12-91 y)</li> <li>≥ 65 y: 21.4%</li> </ul>  | All adult age groups enrolled   | Adults ≥ 65 y   | Adults up to 84 y enrolled<br>Intent is for at least 25% of participants to be 65 years and above  |
| Pregnancy                                    | <ul style="list-style-type: none"> <li>13 pregnancies</li> <li>6 in vaccine group</li> </ul>  | <ul style="list-style-type: none"> <li>23 pregnancies</li> <li>12 in vaccine group</li> </ul>  | Not included in phase 3 trial   | Not included in phase 3 trial   | Not included in phase 3 trial  |
| Racial/ethnicity                             | <p>Demographics of per-protocol efficacy population (11/11) in EUA submission (n = 27,817)<sup>f</sup></p> <ul style="list-style-type: none"> <li>Asian: 4.7%</li> <li>Black: 9.7%</li> <li>Hispanic/Latino: 20%</li> <li>Other: &lt;3%</li> </ul>  | <p>Demographics of evaluable efficacy population in EUA submission (n = 40,277)</p> <ul style="list-style-type: none"> <li>Asian: 4.4%</li> <li>Black: 9.8%</li> <li>Hispanic/Latino: 26.2%</li> <li>Other: &lt;3%</li> </ul>  | In an August 31, press release, AstraZeneca states it “will enroll in excess of 50,000 volunteers including 30,000 in the US, in Latin America, Asia, Europe, Russia, and Africa that will provide data for diverse populations.”   | Phase 3 trial includes, “significant representation of Black, Hispanic/Latinx, American Indian and Alaskan Native participants” | Phase 3 enrollment goals include: <ul style="list-style-type: none"> <li>≥ 15% Black</li> <li>10-20% LatinX</li> <li>1-2% American Indian</li> </ul> |

|  | Vaccine candidates  |   |   |   |  |
|--|---|---|---|---|--|
|  | mRNA vaccines   |   | Replication-defective vectored vaccines   |   | Protein subunit  |
|  | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)   | JNJ-78436735 (J&J)  | NVX-CoV2373 (Novavax)  |
| Pediatrics                                       | <ul style="list-style-type: none"> <li>Not included</li> <li>Phase 2/3 clinical trial (NCT04649151) in adolescents 12 to &lt; 18 y (TeenCove) initiated.</li> <li>Moderna announced on Dec. 10 that the first adolescent participants were dosed</li> </ul>                                       | <p>In EUA submission:</p> <ul style="list-style-type: none"> <li>Children aged ≥ 12 y enrolled</li> <li>Participants aged ≤ 15 y (n = 100) not included in efficacy analysis or EUA request. No primary endpoint occurred in age group.</li> <li>Adolescents aged 16-18 y (n = 283) included in efficacy analysis. Only 1 primary endpoint in age group.</li> </ul> | Children 5-12 y are being recruited in the UK   | Not included in phase 3 trial   | Not included in phase 3 trial  |
| Other special populations included/considered    | <p>Demographics of per-protocol efficacy population (11/11) in EUA submission (n = 27,817)<sup>f,g</sup></p> <ul style="list-style-type: none"> <li>1 high-risk condition present: 22.3%</li> <li>≥ 2 high-risk conditions present: 4%</li> </ul>   | <p>Demographics of evaluable efficacy population in EUA submission (n = 40,277):</p> <ul style="list-style-type: none"> <li>Obesity: 34.8%</li> <li>Diabetes: 8.4%</li> <li>Pulmonary Disease: 7.8%</li> <li>HIV (n = 120) only analyzed in all-enrolled population (not evaluable efficacy or safety populations)</li> </ul>                                       | Stable, pre-existing medical conditions   | Patients with and without comorbidities associated with an increased risk for progression to severe disease   | Up to 400 participants will also receive a licensed seasonal influenza vaccine as part of a co-administration sub study  |
| <b>Phase 3 study endpoints</b>                   |   |   |   |   |  |
| Primary efficacy endpoint (results if available) | <p>EUA submission based on interim (11/11) and final efficacy analyses (11/25)<sup>f</sup></p> <p><b>VE against first occurrence of confirmed symptomatic COVID-19 disease with onset at least 14 d after second dose</b></p> <ul style="list-style-type: none"> <li>Interim: 90 cases</li> </ul> | <p>EUA submission based on final efficacy analysis when a total of 170 confirmed COVID-19 cases accrued.</p> <p><b>First primary endpoint, VE against confirmed COVID-19 in participants without evidence of prior SARS-CoV-2 infection prior to 7 d after second</b></p>   | <p>Nucleic acid amplification test positive COVID-19 with symptomatic illness occurring ≥ 15 d post second dose of study intervention.</p> <ul style="list-style-type: none"> <li>101 cases observed in placebo group vs. 30 cases in the combined LD/SD</li> </ul> | <p>First occurrence of molecularly confirmed <b>moderate to severe/critical COVID-19</b>, with onset at least 14 d post-vaccination in seronegative adults.</p> | <p>Two primary endpoints:</p> <ul style="list-style-type: none"> <li>First occurrence of PCR-confirmed, <b>symptomatic COVID-19</b> with onset at least 7 d after the second dose in volunteers not previously infected with SARS-CoV-2</li> </ul> |

|                                      | Vaccine candidates  |   |  |                    |   |
|--------------------------------------|---|---|--|--------------------|---|
|                                      | mRNA vaccines   |   | Replication-defective vectored vaccines  |                    | Protein subunit   |
|                                      | mRNA-1273 (Moderna)   | mRNA-BNT162b2 (BioNTech/Pfizer)   | AZD1222 (AstraZeneca)  | JNJ-78436735 (J&J) | NVX-CoV2373 (Novavax)   |
|                                      | <p>observed in placebo vs. 5 cases in vaccine group, for a VE point estimate of 94.5% (95% CI, 86.5-97.8%)</p> <ul style="list-style-type: none"> <li>Final: 185 cases observed in placebo group vs. 11 cases in vaccine group, for a VE point estimate of 94.1% (95% CI, 89.3-96.8%).</li> </ul> | <p>dose</p> <ul style="list-style-type: none"> <li>162 cases observed in placebo group vs. 8 cases in vaccine group, for VE point estimate of 95% (95% CI, 90.3-97.5%)</li> </ul> <p><b>Second primary endpoint, VE against confirmed COVID-19 in participants with or without evidence of prior SARS-CoV-2 infection prior to 7 d after dose 2</b></p> <ul style="list-style-type: none"> <li>169 cases observed in placebo group vs. 9 cases in the vaccine group, for VE point estimate of 94.6% (95% CI, 89.9-97.3%)</li> </ul> | <p>and SD/SD group, for a VE point estimate of 70.4%</p> <ul style="list-style-type: none"> <li>2 SD produced a VE of 62.1%</li> <li>1 LD followed by a SD produced a VE of 90%</li> </ul> |                    | <ul style="list-style-type: none"> <li>First occurrence of PCR-confirmed, <b>symptomatic moderate or severe COVID-19</b> with onset at least 7 d after the second dose in volunteers not previously infected with SARS-CoV-2</li> </ul> |
| <b>CPT codes (Payment allowance)</b> | 91301 (\$0.010)<br>0011A (\$16.940)<br>0012A (\$28.390)   | 91300 (\$0.010)<br>0001A (\$16.940)<br>0002A (\$28.390)   | NR   | NR                 | NR  |
| <b>Clinical summary</b>              | Please view the <a href="#">evidence summary</a> for an expanded discussion of data.  |   |  |                    |   |

Abbreviations: ADE = adverse drug event; BU = beyond use; CPT = current procedural terminology; EUA = emergency use authorization; HIV = human immunodeficiency virus; LD = low dose; LNP = lipid nanoparticle; mRNA = messenger ribonucleic acid; NR = not reported; PPE = personal protective equipment; RT = room temperature; SD = standard dose; TBA = to be announced; ULT = ultra-low temperature; VE = vaccine efficacy; VP = viral particle

#### Footnotes

<sup>a</sup> Information is rapidly changing; this is a living document that is updated frequently

<sup>b</sup> A Chinese vaccine against Ebola that uses a simian adenovirus has been granted an EUA

<sup>c</sup> FDA is **advising** that it is acceptable to use every full dose obtainable (6 or 7) from each vial, pending resolution of the issue. However, since the vials are preservative free, it is critical to note that any further remaining product that does not constitute a full dose should not be pooled from multiple vials to create one.

<sup>d</sup> After hearing news reports about reducing the number of doses, extending the length of time between doses, changing the dose (half-dose), or mixing and matching vaccines, the FDA published a **statement** that “the available data continue to support the use of 2 specified doses of each authorized vaccine at specified intervals.”

<sup>e</sup> These persons should not receive mRNA COVID-19 vaccination at this time unless they have been evaluated by an allergist-immunologist and it is determined that the person can safely receive the vaccine (e.g., under observation, in a setting with advanced medical care available).

<sup>f</sup> Two datasets were submitted: November 11, 2020 dataset (interim data) and November 25, 2020 dataset (final data). The FDA validated November 11 dataset only; however, results between datasets were consistent

<sup>g</sup> High risk is defined as patients who meet at least one of the following criteria (protocol-defined): Chronic lung disease (eg, emphysema and chronic bronchitis, idiopathic pulmonary fibrosis, and cystic fibrosis) or moderate to severe asthma; Significant cardiac disease (eg, heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, and pulmonary hypertension); Severe obesity (body mass index  $\geq 40$  kg/m<sup>2</sup>); Diabetes (Type 1, Type 2, or gestational); Liver disease; HIV

## Evidence summary: COVID-19 vaccines

### Introduction

On May 15, 2020, Operation Warp Speed (OWS) – a partnership among the Department of Health and Human Services (HHS), the Department of Defense (DoD), and the private sector – was announced with the goal to advance the development, manufacture, and distribution of vaccines, therapeutics, and diagnostics to combat the COVID-19 pandemic. In addition to providing financial support, the OWS has committed to work in parallel with the U.S. FDA to ensure that safe and effective candidates are taken through the necessary steps to obtain approval or authorization. The goal of the initiative is to deliver 300 million doses of a safe and effective vaccine against COVID-19 by January 2021.<sup>1</sup> To meet this goal, OWS plans to support the development and eventual distribution of the most promising 8 vaccine candidates (2 candidates per vaccine platform technology) produced from 1 of 4 vaccine platform technologies: the mRNA platform, the replication-defective live-vector platform, the recombinant-subunit-adjuvanted protein platform, or the attenuated replicating live-vector platform.<sup>2</sup> These platforms are considered ideal because they support rapid development from viral sequencing to clinical trials (<16 weeks) and are suitable for large-scale manufacture using pathogen agonistic technology.<sup>3</sup> To date, partnerships have been executed with Moderna and Pfizer/BioNTech (both mRNA), AstraZeneca and Janssen (both replication-defective live-vector), and Novavax and Sanofi/GSK (both recombinant-subunit-adjuvanted protein).<sup>2</sup> The federal government has made investments to expand domestic manufacturing capabilities for vaccine candidates and specialized materials (eg, syringes, vials) and is planning/building the necessary infrastructure to support vaccine distribution.

On June 30, 2020, the U.S. FDA published **guidance** that outlines key considerations for the development and licensure of a safe and effective vaccine against COVID-19.<sup>4</sup> In its guidance, the FDA recommends that the point estimate for vaccine efficacy against placebo should be at least 50%. The FDA also recommends that all phase 3 vaccine trials employ best methodology for trial design, enroll at least 3,000 patients to ensure the sample is sufficiently large to evaluate prelicensure safety, and enroll diverse patient populations. It is likely that a COVID-19 vaccine will be reviewed in real-time and eventually approved under a Biologics License Application. However, the FDA will consider issuing an Emergency Use Authorization (EUA) for a vaccine candidate on a case-by-case basis. On October 6, 2020, the FDA released additional **guidance** to inform industry regarding the data and information needed to support the issuance of an EUA.<sup>5</sup> Notable in this guidance, the FDA suggests that in order to issue an EUA, efficacy data from an interim analysis must meet the prespecified success criteria for the study's primary endpoint and data from phase 3 trials should include, at minimum, a median of 2 months of follow-up after the completion of the full vaccine regimen to provide adequate information to assess safety and efficacy. The FDA's Vaccines and Related Biological Products Advisory Committee is expected to provide an independent review and recommendation to the FDA on the scientific and technical merits of a vaccine candidate.<sup>6</sup> However, the FDA will be solely responsible for making the decision for or against approval of a vaccine candidate.

The average timeline for developing a new vaccine is 10 years.<sup>7</sup> However, most expect a vaccine against COVID-19 to be approved for commercial use in record time. One of the factors that has enabled rapid development is previous

investments in new vaccine technology platforms, such as nucleotide- and adenovirus-based approaches.<sup>7</sup> Both platforms offer theoretical manufacturing advantages compared to established platforms in speed and scalability. Development time has also been reduced by executing vaccine development steps simultaneously (or in parallel) versus in a linear sequence. For example, vaccine platforms that have been previously evaluated in humans may proceed to phase 1 clinical trials without waiting for confirmatory results from animal models.<sup>3</sup> Because of financial and technology investments from the federal government, manufacturers of late-stage vaccine candidates have been able to scale production to commercial levels before proof of substantial safety and immunogenicity data are available.<sup>3</sup> Lastly, maximizing enrollment and location of phase 3 trials ensures that event-driven trials can demonstrate efficacy (or lack thereof) rapidly.

The demand for a COVID-19 vaccine is expected to initially exceed supply. The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccines Work Group convened an emergency meeting on December 1, 2020, to determine the phased allocation of COVID-19 vaccines in the event of an FDA approval. Using the pillars – science, implementation, and ethics – ACIP approved the following recommendation by a majority vote (13-1) at its emergency meeting: “When a COVID-19 vaccine is authorized by FDA and recommended by ACIP, vaccination in the initial phase of the COVID-19 vaccination program (Phase 1a) should be offered to both 1. health care personnel and 2. residents of long-term care facilities.” The recommendation has been adopted by the Centers for Disease Control and Prevention (CDC) Director.<sup>8</sup> On December 20, 2020, the ACIP updated interim vaccine allocation recommendations to include Phases 1b and 1c. In Phase 1b, COVID-19 vaccine should be offered to persons aged 75 and older and non-health care frontline essential workers. In Phase 1c, the vaccine should be offered to persons aged 65 to 74 years, persons aged 16 to 64 years with high-risk medical conditions, and essential workers not included in Phase 1b.<sup>9</sup>

## **Side-by-side document**

The side-by-side document is a living document intended to provide the most up-to-date clinical information. As information is changing rapidly, the document will be updated frequently. The document provides a brief summary of safety and efficacy of late-stage vaccine candidates.

## **Efficacy and safety considerations**

In order to meet the criteria for FDA approval, initial vaccine candidates will need to demonstrate a reduction in the rate of symptomatic COVID-19 disease by 50%.<sup>4</sup> Of note, the FDA has not historically recommended numerical end point estimates for licensure, but the agency has developed endpoint criteria prospectively for COVID-19 vaccines to increase confidence in the efficacy of a COVID-19 vaccine.<sup>6</sup> Secondly, most trials will assess vaccine efficacy to prevent severe COVID-19. Once it is known which immune responses are reasonably likely to predict protection against COVID-19, it is expected that COVID-19 vaccines will be approved based on surrogate immunogenicity endpoints, similar to other vaccines against respiratory pathogens.<sup>3</sup> In collaboration with the National Institute of Allergy and Infectious Diseases, the Coronavirus Prevention Network, and sponsor companies, OWS has harmonized trial endpoints and assay readouts to



permit the indirect comparison among findings from phase 3 trials – with the caveat that indirect comparisons have limitations.<sup>2</sup>

Preclinical experience with vaccine candidates for Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS) has raised concerns about exacerbating lung disease, which is likely mediated through antibody-dependent enhancement or a type 2 helper T-cell response.<sup>7</sup> Therefore, rigorous safety monitoring of all COVID-19 vaccine candidates is required. The FDA recommends that only vaccine candidates that demonstrate robust neutralizing antibody titers and Th1-type T cell polarization proceed to human trials and that all late phase COVID-19 vaccine studies conduct interim analysis to survey for the development of enhanced respiratory disease, which may be indicative of vaccine-induced immunopathology.<sup>4</sup>

## Late-stage vaccine candidates

### mRNA-1273

mRNA-1273 is a nucleotide-based vaccine candidate that utilizes Moderna's mRNA technology platform. It encodes for a prefusion stabilized form of the full-length SARS-CoV-2 spike (S) protein. Due to the labile nature of mRNA, it is encapsulated and delivered via a lipid nanoparticle (LNP) carrier. Once the vaccine is injected into the muscle, myocytes take up the LNP carrier and release the mRNA into the cytoplasm for translation into the S protein. Subsequent development of anti-S protein antibodies by the immune system may prevent infection by blocking the S protein from binding to its receptor.<sup>10</sup> While none of Moderna's mRNA vaccine candidates are FDA approved for commercial use, multiple mRNA vaccines that use its platform are currently in human clinical trials.

The clinical development program for mRNA-1273 consists of 3 trials: a phase 1 ([NCT04283461](#)), phase 2 ([NCT04405076](#)), and a phase 3 ([NCT04470427](#)) trial. All trials have been initiated and are currently active. Descriptions of the study methodology and results (if available) are presented in [Appendix A](#). Moderna entered its phase 1 clinical trial on March 16, 2020 less than 10 weeks after the first genetic sequence for SARS-CoV-2 was released. Two of the expected 3 reports from the phase 1 trial have been published –interim analyses of the safety and immunogenicity of mRNA-1273 in the 18 to 55 years of age old cohort and in the 56 years of age or older cohort through day 57 – and results are briefly summarized in the next section. The third and final report will summarize the safety and durability of immunity for both study cohorts for up to 1 year after the second dose of the vaccine.<sup>11</sup>

A phase 2 trial was initiated in May and is expected to enroll 600 healthy participants aged 18 years and older. Participants will be randomized to receive mRNA-1273, given as 2 doses of 50 mcg or 100 mcg, or a matching placebo. The primary outcome measures are the occurrence of solicited and unsolicited safety events and the titer of SARS-CoV-2-specific binding antibodies up to 1 year after the final dose.<sup>12</sup>

The phase 3 trial was initiated in July and results were recently published in the [New England Journal of Medicine](#).<sup>13</sup> Enrollment is complete and the final sample size is 30,000 participants. Assuming an attack rate of 0.75% in the placebo group, 151 symptomatic COVID-19 cases will provide 90% power to demonstrate 60% vaccine efficacy (VE) against

symptomatic COVID-19 illness (with a lower bound of the VE confidence interval to exceed 30%). Two interim analysis are planned once 35% and 70% of total target cases occur. The primary efficacy objective of the trial can be achieved if the corresponding confidence for VE rules out less than 30% efficacy at either of the interim analyses or at the primary analysis.<sup>14</sup> Additional information on the trial is presented in **Appendix A**.

## **Efficacy**

Published interim results of phase 1 data<sup>15</sup> from the 18 to 55 year old cohort suggest that all participants achieved seroconversion for binding antibodies, regardless of dose administered (25 mcg, 100 mcg, 250 mcg) by day 15 after the first dose of vaccine; however, the magnitude of the antibody response was time and dose dependent. The median magnitude of the antibody response in the 100-mcg and 250-mcg dose group was similar to the median magnitude of response in human convalescent plasma samples (HCS) after the first dose of the vaccine and in all dose groups, the median magnitude of the antibody response after the second dose was in the upper quartile of the values seen with convalescent plasma. Antibody neutralizing activity, measured by pseudovirus and live virus neutralization assays, was achieved in all participants after the second dose of the vaccine. Similarly, the magnitude of neutralization activity was also dose dependent. In the 100-mcg and 250-mcg dose groups, the magnitude of neutralizing activity after the second dose was similar to values seen in the upper half of the distribution of values for HCS. In addition to evaluating humoral response (ie, neutralizing antibody titers), cellular immunity was also evaluated. mRNA-1273 demonstrated Th1-type T cell polarization with minimal Th2 cytokine expression.<sup>15</sup>

Moderna published interim reactogenicity and immunogenicity results from its phase 1 data from the 56 years or older cohort. The cohort was small; only 20 patients received 2-doses of the 100-mcg phase 3 dose (results from the 25-mcg older cohort are not discussed here.). Similar to the younger cohort, the magnitude of antibody response was time and dose dependent. Additionally, binding antibody responses, though based on a small sample size, appeared to be age independent. At day 57, the GMTs for binding antibody responses in participants between 56 and 70 years of age and those 71 years of age or older far exceeded the responses observed among those who donated HCS. Antibody neutralizing activity, measured by 3 live-virus neutralization methods, was undetectable at baseline in all 20 participants. By day 43 (14 days after the second dose), all participants experienced a robust neutralizing response that was age independent in 2 of 3 assays. In the plaque reduction neutralization test (80% neutralization), neutralization responses were higher in those 56 to 70 years of age compared to those 71 years of age or older.<sup>16</sup> Like the younger cohort, older cohorts also demonstrated Th1-type T cell polarization after vaccination with mRNA-1273.

Results from the phase 3 trial are necessary to confirm that the humoral and cellular responses elicited by mRNA-1273 confer protection against COVID-19. Moderna submitted an EUA application on November 30 (2 data sets: interim data set with 7 weeks of safety data – November 11; final dataset with 9 weeks of safety data – November 25) and the Vaccines and Related Biological Products Advisory Committee panel voted in favor of EUA approval on December 17. The FDA issued an EUA for mRNA-1273 on December 18, 2020. The primary endpoint of the phase 3 trial evaluated the incidence of protocol-defined COVID-19 occurring at least 14 days after the second dose in participants with negative SARS-CoV-2 status at baseline. The protocol defined COVID-19 as at least 2 systemic symptoms (fever ( $\geq 38^{\circ}\text{C}$ ), chills, myalgia, headache, sore throat, new olfactory and taste disorders) OR at least 1 respiratory sign/symptom (cough,

shortness of breath or difficulty breathing, OR clinical radiographic evidence of pneumonia) AND nasopharyngeal swab, nasal swab, or saliva sample (respiratory sample if hospitalized) positive for SARS-CoV-2 by RT-PCR. COVID-19 cases were adjudicated by a blinded committee. In the per-protocol set (n = 27,817) at the first pre-specified interim analysis, there were 5 and 90 adjudicated COVID-19 cases in the vaccine and placebo groups, respectively (VE of 94.5%; 95% CI, 86.5-97.8%). In the per-protocol set (n = 27,817) at the final scheduled efficacy analysis, there were 11 and 185 adjudicated COVID-19 cases in the vaccine and placebo groups, respectively (VE of 94.1%; 95% CI, 89.3-96.8%). The FDA has not validated the final efficacy results for the EUA submission. Results from the interim and final efficacy analysis of the primary endpoint are consistent and met the prespecified success criterion (true VE > 30%). While the occurrence of COVID-19 in patients with evidence of prior SARS-CoV-2 infection at study enrollment was evaluated as a secondary endpoint, too few patients at baseline had evidence of prior infection (approximately 2.2% of the population) and data are insufficient to draw any conclusions regarding efficacy in those with prior infection. The FDA analyzed results of the primary endpoint at the first pre-specified interim analysis by baseline risk for severe COVID-19, regardless of age and found that VE against COVID-19 was consistent in those at risk for developing severe COVID-19 due to a baseline comorbidity (VE: 95.9%; 95% CI, 69.7-99.4%). While multiple subgroup analyses by high-risk baseline comorbidity were conducted, groups stratified by baseline comorbidity were small and the trial lacked sufficient power to reach conclusions.<sup>17,18</sup>

Multiple subgroup analyses of the primary endpoint at the pre-specified interim analysis were performed and are summarized in Table 1. Of note, while the VE against COVID-19 was consistent across age cohorts in the interim analysis, at the final scheduled efficacy analysis (results not shown in the table), the VE in participants aged 65 years and older (VE: 86.4%; 95% CI, 61.4-95.5%) was lower than the VE in those aged less than 65 years (VE: 95.6%; 95% CI, 90.6-97.9%). This may be due to the lower number of COVID-19 cases (n = 33) and participants (n = 7,135) in the ≥ 65 years old cohort. Many subgroups were too small to reach firm conclusions about VE against COVID-19.<sup>17,18</sup>

**Table 1: Subgroup analyses of vaccine efficacy, COVID-19 14 days after dose 2 per adjudication committee assessments, per-protocol set (pre-specified interim analysis)<sup>17</sup>**

| Efficacy endpoint subgroup                    | Vaccines cases (no. at risk) | Placebo cases (no. at risk) | Vaccine Efficacy % (95% CI) |
|---|------------------------------|-----------------------------|-----------------------------|
| Age group (years)                             |                              |                             |                             |
| 18 to <65                                     | 5 (10407)                    | 75 (10384)                  | 93.4% (83.7,97.3)           |
| 65 to <75                                     | 0 (2904)                     | 12 (2823)                   | 100%                        |
| 75 and older                                  | 0 (623)                      | 3 (676)                     | 100%                        |
| Age and risk for severe COVID-19 <sup>a</sup> |                              |                             |                             |
| 18 and <65 and not at risk                    | 4 (8309)                     | 57 (8323)                   | 93% (80.8,97.5)             |
| 18 and <65 and at risk                        | 1 (2098)                     | 18 (2061)                   | 94.6% (59.4,99.3)           |

|                                  |              |               |                   |
|----------------------------------|--------------|---------------|-------------------|
| ≥ 65                             | 0<br>(3527)  | 15<br>(3499)  | 100%              |
| Ethnicity                        |              |               |                   |
| Hispanic or Latino               | 0<br>(2783)  | 12<br>(2769)  | 100%              |
| Not Hispanic or Latino           | 5<br>(11019) | 77<br>(10987) | 93.6% (84.1,97.4) |
| Race                             |              |               |                   |
| American Indian or Alaska native | 0<br>(107)   | 0<br>(110)    | --                |
| Asian                            | 0<br>(616)   | 3<br>(684)    | 100%              |
| Black or African American        | 0<br>(1369)  | 4<br>(1338)   | 100%              |
| White                            | 5<br>(11078) | 80<br>(11005) | 93.8% (84.8,97.5) |

<sup>a</sup>High risk is defined as patients who meet at least one of the following criteria (protocol-defined): Chronic lung disease (eg, emphysema and chronic bronchitis, idiopathic pulmonary fibrosis, and cystic fibrosis) or moderate to severe asthma; Significant cardiac disease (eg, heart failure, coronary artery disease, congenital heart disease, cardiomyopathies, and pulmonary hypertension); Severe obesity (body mass index ≥40 kg/m<sup>2</sup>); Diabetes (Type 1, Type 2, or gestational); Liver disease; HIV

Protocol-defined severe COVID-19 disease, defined as a case with at least 1 of the following – clinical signs at rest indicative of severe systemic illness; respiratory failure or Acute Respiratory Distress Syndrome; evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; admission to an ICU; or death – occurred in 30 participants at the time of the final analysis (0 in the vaccine group and 30 in the placebo group) for a VE point estimate against severe COVID-19 disease of 100%. There was 1 death in the placebo group adjudicated as COVID-19 related. While no COVID-19 cases in vaccine recipients were adjudicated as severe, 1 vaccine recipient met the definition for severe COVID-19 disease based on symptoms, but had a negative SARS-CoV-2 test at hospitalization with evidence of a positive SARS-CoV-2 test at an outside facility.<sup>18</sup>

Cumulative incidence curves for the first COVID-19 occurrence started to diverge between vaccine and placebo recipients around 14 days after dose. While there appears to be some protection after dose 1 (VE: 50.8%; 95% CI, -53.6-86.6%), the durability of VE after a single dose is unknown because most participants received a second dose.<sup>17</sup>

## Safety

Phase 1 safety results: All 3 doses of mRNA-1273 were well tolerated in the 18 to 55-year-old cohort.<sup>15</sup> In general, solicited systemic and local adverse events were more commonly reported after the second dose. After the first dose, solicited systemic adverse events (arthralgia, fatigue, fever, chills, headache, myalgia, nausea) were mild to moderate in severity. Solicited local adverse events (redness/erythema, induration/swelling, pain at injection site) were mostly rated as mild to moderate in severity after both the first and second doses; however, size of erythema/redness was rated as severe in a small proportion of participants in the 100-mcg and 250-mcg groups after the first and second doses. No participant had a fever after the first dose. A fever after the second dose was documented in 40 to 57% of participants in the 100-mcg and 250-mcg groups, respectively. Across both vaccine doses, adverse events that occurred in greater than 50% of

participants included fatigue, chills, headache, myalgia, and pain at the injection site. There were no potential safety signals based on reports of unsolicited adverse events or clinical laboratory values.<sup>15</sup>

The reactogenicity profile of mRNA-1273 in the older cohort was not qualitatively different from its profile in the younger cohort. In the older cohorts, the most common solicited adverse events were headache, fatigue, myalgia, chills, and injection-site pain. The occurrence of adverse events was more common after the second dose. All the 10 solicited local adverse events and all but 2 of the systemic events that were rated as moderate in severity and occurred after the administration of the second dose. Most symptoms occurred within 1 to 2 days of vaccination and resolved quickly; however, 3 patients experienced erythema for 5 to 7 days and 1 participant reported myalgia for 5 days. There were no potential safety signals based on reports of unsolicited adverse events or clinical laboratory values.<sup>15</sup>

Phase 3 safety results: In the pre-specified, safety interim analysis (n = 30,350, median follow-up 7 weeks) the most common local and systemic solicited adverse events that occurred within 7 days of a dose were injection site pain (91.6%), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint pain (44.8%), and chills (43.4%). In general, local solicited adverse events occurred at a similar incidence after the first and second dose and the majority were grade 1 to 2 in severity. Most local events occurred within the first 2 days of vaccination and persisted for a median of 1 to 3 days, although some local events persisted for greater than 7 days and were most likely dermal hypersensitivity reactions. Systemic adverse events occurred at a higher incidence and severity after the second dose. Most solicited systemic adverse events occurred within 2 days after an injection and lasted for 1 to 3 days. Grade 3 events that occurred at a 2% or greater frequency after the first dose included injection site pain (2.8%) and after the second dose included fatigue (9.7%), myalgia (8.8%), arthralgia (5.2%), headache (4.5%), injection site pain (4.1%), and erythema/redness at the injection site (2.0%). Severe adverse events were generally less frequent in participants aged 65 years and older.<sup>17,18</sup>

The incidence of unsolicited adverse events (dataset cutoff of November 25, median follow-up of 9 weeks) that occurred up to 28 days after an injection were comparable between vaccine and placebo recipients with the exception of a numeric imbalance in the occurrence of lymphadenopathy (1.1% vaccine, 0.63% placebo) and local hypersensitivity reactions (1.5% vaccine, 1.1% placebo). There were 4 cases of Bell's palsy (3 vaccine, 1 placebo). While there appears to be no causal relationship between the vaccine and Bell's Palsy, the FDA recommends continued surveillance. A total of 13 deaths (6 vaccine, 7 placebo) have been reported up to December 3; none of the deaths are considered related to vaccine or placebo.<sup>17,18</sup>

## BNT 162b2

BNT162b2 is an LNP formulated, nucleoside-modified messenger RNA (modRNA) vaccine. While the LNPs help protect the mRNA against enzymatic degradation and ensure efficient cellular uptake, the N-methyl pseudouridine (m1Ψ) nucleoside modification dampens immune sensing and assists in providing increased RNA translation in vivo. The vaccine encodes the SARS-CoV-2, full-length, spike glycoprotein, stabilized in its prefusion conformation (P2 S).<sup>19</sup>

BNT162b2 is 1 of 4 vaccine candidates in the Pfizer/BioNTech BNT162 vaccine platform.<sup>20</sup> Two of the vaccine candidates—BNT162b1 and BNT162b2—were included in phase 1 of the ongoing phase 1/2/3, randomized, placebo-controlled, observer-blind clinical trial ([NCT04368728](#)). The study has been conducted in 2 parts—phase 1 and phase 2/3.

The goal of phase 1 was to examine immuno- and reactogenicity of the vaccines and to identify the preferred vaccine candidate and dose level, while phase 2/3 is an expanded cohort with the primary goal of determining VE.<sup>21</sup>

### **Efficacy and safety: Phase 1**

Results from the phase 1 trial were published **online** on October 14, 2020. Healthy adults (n = 195), aged 18 to 55 and 65 to 85, were randomized to receive placebo or 1 of the vaccine candidates: BNT162b1 or BNT162b2, at dose levels of either 10 mcg, 20 mcg, or 30 mcg. Study participants received 2 doses of their assigned intervention (placebo or vaccine candidate), 21 days apart. One group of 18 to 55-year-old participants was randomized to receive a single dose of 100 mcg BNT162b1. In total, there were 13 groups with 15 participants each<sup>21</sup>(refer to **Appendix B** for further detail).

Investigators examined antigen (receptor binding domain or S1)-binding IgG and neutralizing antibody responses in participants at days 0, 21, 28, and 35 (sera were obtained prior to vaccination on days 0 and 21). Immunogenicity data from a human convalescent serum (HCS) panel (n = 38 donors with PCR-confirmed SARS-CoV-2) served as a benchmark against which the immune response in trial participants was evaluated.<sup>22</sup>

Ultimately, BNT162b1 and BNT162b2 were found to elicit similar dose-dependent SARS-CoV-2 neutralizing geometric mean titers (GMTs), comparable to or higher than GMTs in the HCS panel. Antigen-binding IgG and neutralizing responses were boosted by the administration of dose 2 with both vaccine candidates at the 30-mcg dose level, providing justification for administration of a second dose of vaccine. Lower antigen-binding IgG and neutralizing responses were observed in the 65 to 85 year old age group as compared to the 18 to 55 year old age group; specifically, in looking at neutralization titers for both vaccine candidates at the 30 mcg dose level on days 28 and 35 (the days on which the highest neutralization titers were observed), the 50% neutralizing GMTs ranged from 1.7 – 4.6 times the GMT of the HCS panel for participants age 18 – 55 years and from 1.1 – 2.2 times the GMT of the HCS panel for participants age 65 – 85 years.<sup>22</sup>

From a safety standpoint, local reactions reported within 7 days of vaccination were largely mild to moderate and consisted primarily of pain at the injection site; local reactions were more frequent after the second dose. No older adults who received BNT162b2 reported redness or swelling and there were no reports of a grade 4 local reaction (e.g. necrosis or exfoliative dermatitis) in any group. As far as systemic events, only 17% of participants in the 18 to 55 year old group and 8% of participants in the 65 to 85 year old group experienced a fever with dose 2 of 30 mcg BNT162b2 as compared to 75% and 33% of participants receiving dose 2 of 30 mcg BNT162b1 in those same respective age groups. Ultimately, the milder systemic reactogenicity of BNT162b2—along with the comparable antibody responses noted between the 2 vaccine candidates—led to the selection of BNT162b2 to move into phase 2/3 studies.<sup>22</sup>

### **Phase 2/3 Study**

The BNT162b2 vaccine trial moved into phase 3 in July 2020, with the initial intent of enrolling 30,000 participants aged 18 to 85 years; however, in subsequent months, the protocol was amended to expand enrollment to 44,000 participants—including persons as young as 12 years of age and participants with chronic, stable HIV, Hepatitis C, or Hepatitis B.<sup>23,24</sup>

For phase 2/3, evaluation of VE is the primary objective. Under the assumption of a true VE of 60% and an attack rate of 1.3% illness rate per year in the placebo group, it was estimated that a total of 164 COVID-19 cases (estimated accrual: 6 months) would provide 90% power to conclude a true VE >30% with high probability. It was noted that if the attack rate were much higher, the case accrual could be more rapid, allowing for the study's primary endpoint to be assessed much sooner. There were 4 interim analyses (IAs) planned, which will occur after accrual of 32, 62, 92, and 120 cases; however, the first planned IA was not conducted for operational reasons, leaving the remaining 3 IAs (at 62, 92, and 120 cases) to be completed. Vaccine efficacy for the first primary objective (see **Appendix B** for further detail on hierarchical analysis of endpoints) was to be evaluated at each IA, with the potential for efficacy to be declared if the VE point estimate for the current number of cases were met, which would be indicative of VE>30%.<sup>25</sup>

Pfizer submitted an EUA application on November 20 (data cutoff for EUA submission was November 14) and the Vaccines and Related Biological Products Advisory Committee panel voted in favor of EUA approval on December 10. The FDA granted emergency use on December 11. Pfizer/BioNTech published results from the ongoing phase 2/3 trial in the *New England Journal of Medicine*<sup>26</sup> and both the FDA<sup>27</sup> and Pfizer/BioNTech presented separate analyses of the phase 2/3 data during the Vaccines and Related Biological Products Advisory Committee meeting. The first and second primary endpoints of the phase 2/3 trial evaluated the occurrence of confirmed COVID-19 with onset at least 7 days after the second dose in participants without and with and without previous SARS-CoV-2 infection, respectively. Confirmed COVID-19 was defined as the presence of at least 1 of the following symptoms - fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting - combined with a respiratory specimen positive for SARS-CoV-2 within  $\pm$  4 days of symptom onset. In the cohort of participants without evidence of existing or prior SARS-CoV-2 infection (n = 36,258), a primary endpoint occurred in 8 and 162 vaccine- and placebo-recipients, respectively for a VE of 95% (95% CI, 90.3-97.6). In those participants with and without evidence of prior SARS-CoV-2 infection (n = 40,137), an endpoint occurred in 9 vaccine recipients and 169 placebo recipients for a VE of 94.6% (95% credible interval, 89.9-97.3). Results from the first and second primary endpoints met the prespecified success criterion (true VE > 30%).<sup>25</sup> It should be noted that only 3% of participants had evidence of prior infection at study enrollment and few COVID-19 cases occurred in these participants. Because there were too few COVID-19 cases in patients with evidence of prior SARS-CoV-2, efficacy data cannot be interpreted for this subgroup.<sup>26</sup> The FDA analyzed results of the first primary endpoint (patients without prior SARS-CoV-2 infection) by baseline co-morbidity and found that VE point estimates in patients with any co-morbidity (95.3%, 95% CI, 87.7-98.8), any malignancy (75.7%; 95% CI, -145.8-99.5), cardiovascular disease (100%; 95% CI, -0.8-100), chronic pulmonary disease (93%; 95% CI, 54.1-99.8), diabetes (94.7%, 95% CI, 66.8-99.9), and obesity (95.4%; 95% CI, 86-91) were consistent with the VE point estimate for the overall population; however, many groups were small and the trial lacked sufficient power to reach firm conclusions.<sup>27</sup>

Multiple subgroup analyses of the second primary endpoint (recipients with and without prior SARS-CoV-2 infection) were performed and are summarized in Table 2. In general, VE point estimates were high and comparable to that of the overall population, but some subgroups were too small to confirm efficacy.

**Table 2: Subgroup analyses of second primary endpoint: First COVID-19 occurrence  $\geq$  7 days after second dose in participants with and without evidence of SARS-CoV-2 infection (FDA analysis)<sup>27</sup>**

| Efficacy endpoint subgroup       | BNT162b2 cases<br>(no. at risk) | Placebo cases<br>(no. at risk) | Vaccine Efficacy % (95% CI) |
|----------------------------------|---------------------------------|--------------------------------|-----------------------------|
| Overall                          | 9<br>(18,559)                   | 169<br>(18,708)                | 94.6 (89.6,97.6)            |
| Age group (years)                |                                 |                                |                             |
| 16 to 17                         | 0<br>(58)                       | 1<br>(61)                      | 100 (-3969.9,100)           |
| 18 to 64                         | 8<br>(14443)                    | 149<br>(14566)                 | 94.6 (89.1,97.7)            |
| 65 to 74                         | 1<br>(3239)                     | 14<br>(3255)                   | 92.9 (53.2,99.8)            |
| $\geq$ 75                        | 0<br>(805)                      | 5<br>(812)                     | 100 (-12.1,100)             |
| Ethnicity                        |                                 |                                |                             |
| Hispanic or Latino               | 3<br>(5074)                     | 55<br>(5090)                   | 94.5 (83.2,98.9)            |
| Not Hispanic or Latino           | 6<br>(13380)                    | 114<br>(13509)                 | 94.7 (88.1,98.1)            |
| Race                             |                                 |                                |                             |
| American Indian or Alaska native | 0<br>(104)                      | 1<br>(104)                     | 100 (-3511,100)             |
| Asian                            | 1<br>(796)                      | 4<br>(808)                     | 74.4 (-158.7,99.5)          |
| Black or African American        | 0<br>(1758)                     | 7<br>(1758)                    | 100 (30.4,100)              |
| White                            | 7<br>(15294)                    | 153<br>(15473)                 | 95.4 (90.3, 98.2)           |

Severe COVID-19 disease, defined as a case with at least 1 of the following - clinical signs at rest indicative of severe systemic illness; respiratory failure; evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; admission to an ICU; or death – occurred in 4 recipients at least 7 days after the second dose (1 in the vaccine group and 3 in the placebo group)<sup>27</sup> and in 10 recipients after the first dose (1 in the vaccine group and 9 in the placebo group).<sup>26</sup> Due to the small number of severe COVID-19 disease cases, the numeric trend favored BNT162b2, but efficacy cannot be confirmed (VE: 66.4%, 95% CI, -124.8-96.3). The single vaccine recipient met the case definition for severe COVID-19 disease because oxygen saturation was 93% on room air. To date, no COVID-19-related deaths have occurred.<sup>27</sup>

Cumulative incidence curves for first COVID-19 illness suggest divergence between vaccine and placebo recipients around 14 days after dose 1. Because most patients received a second dose, the durability of VE after a single dose is unknown. The median follow-up time at EUA submission is 2 months and the VE response has been durable.<sup>27</sup>



In the reactogenicity subset (n = 8,183) solicited local and systemic adverse events that occurred within 7 days after the receipt of vaccine or placebo were evaluated by self-report in an e-diary.<sup>26</sup> The most common solicited adverse drug reactions were injection site reactions (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), and fever (14.2%).<sup>27</sup> Pain at the injection site was the most common local adverse event and occurred more frequently in the recipients aged ≤ 55 years old compared to those aged > 55 years old. Pain was mild to moderate in severity with less than 1% of recipients reporting severe pain. Most injection site pain resolved within 1 to 2 days. The frequency and severity of systemic adverse drug reactions were higher in recipients aged ≤ 55 years old (vs. > 55 years old). Within all age groups, systemic events occurred more frequently after dose 2 (vs. dose 1) except for vomiting and diarrhea.<sup>26,27</sup> Although the frequency of severe systemic adverse drug reactions was generally less than 2% after any dose, 2 grade 3 adverse reactions were reported at a frequency greater than or equal to 2% after the second dose: fatigue (3.8%) and headache (2.0%).<sup>26</sup> In the main safety population that was followed for at least 2 months after the second dose (n = 37,706), reports of lymphadenopathy (64 vaccine, 6 placebo) and Bell's Palsy (4 vaccine, 0 placebo) were imbalanced between groups.<sup>26,27</sup> While there appears to be no causal relationship between the vaccine and Bell's Palsy, FDA recommends continued surveillance. Four serious adverse events were considered related to vaccine administration by a site investigator including shoulder injury, lymphadenopathy, ventricular arrhythmia, and leg paresthesia. A total of 6 participants (2 vaccine, 4 placebo) died during the follow-up period; none of the deaths were considered related to vaccine or placebo.<sup>26, 27</sup>

## mRNA vaccines – Anaphylaxis reactions

The CDC has received numerous reports of anaphylaxis outside of clinical trials after vaccination with BNT162b2 and mRNA-1273. Between December 14 and December 23, 2020, the incidence of anaphylaxis with BNT162b2 was 11.1 cases per million doses; 71% of the 29 cases occurred within 15 minutes of vaccination.<sup>28</sup> Due to the risk of anaphylaxis, the CDC recommends the following emergency equipment be available for assessing and managing anaphylaxis at any site where the vaccine is administered: epinephrine prefilled syringe or autoinjector, H1 antihistamine, blood pressure cuff, stethoscope, and timing device to assess pulse. While not required, if feasible, the CDC additionally recommends that sites have a pulse oximeter, oxygen, bronchodilator, H2 antihistamine, intravenous fluids, intubation kit, and an adult-sized pocket mask with one-way valve.<sup>29</sup> For more information on managing anaphylaxis associated with mRNA COVID-19 vaccines, please consult the CDC's [interim guidance](#).

The CDC currently advises that mRNA COVID-19 vaccines should not be administered to individuals who have experienced a severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or an immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol and polysorbate).<sup>30</sup> Inactive components of the mRNA COVID-19 vaccines are listed in Table 3. Although the specific vaccine component(s) responsible for anaphylaxis is/are unknown, both vaccines contain polyethylene glycol, which has been known to cause anaphylaxis. Further study is required to establish causality between polyethylene glycol and anaphylaxis; however, immediate allergic reactions to polyethylene glycol or polysorbate (due to potential cross-reactive hypersensitivity) are considered a contraindication to vaccination with an mRNA COVID-19 vaccine.<sup>30</sup> While neither the CDC or the American College of Allergy, Asthma, and Immunology (ACAAI) consider a

history of allergic reactions to any other vaccine or injectable therapy a contraindication to vaccination with an mRNA COVID-19 vaccine, both advise that vaccination should be undertaken using professional judgement and in consultation with the patient. Patients with common allergies to medications, foods, inhalants, insects and latex are not assumed to be at greater risk for experiencing anaphylaxis compared to the general public.<sup>30,31</sup> As information is rapidly changing, the CDC and ACAAI will update guidance.

**Table 3: Ingredients in mRNA COVID-19 vaccines<sup>30</sup>**

| Description            | BNT162b2 (Pfizer-BioNTech COVID-19 vaccine)                                      | mRNA-1273 (Moderna COVID-19 vaccine)   |
|------------------------|--|--|
| mRNA                   | Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2 |  |
| Lipids                 | 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide                         | PEG2000-DMG: 1,2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol                      |
|                        | 1,2-distearoyl-sn-glycero-3-phosphocholine                                       | 1,2-distearoyl-sn-glycero-e-phosphocholine   |
|                        | Cholesterol  | Cholesterol  |
|                        | (4-hydroxybutyl)azanediylbis(hexane-6,1-diyl)bis(2-hexyldecanoate)               | SM-102: heptadecane-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate |
| Salts, sugars, buffers | Potassium chloride   | Tromethamine   |
|                        | Monobasic potassium phosphate  | Tromethamine hydrochloride   |
|                        | Sodium chloride  | Acetic acid  |
|                        | Dibasic sodium phosphate dihydrate   | Sodium acetate   |
|                        | Sucrose  | Sucrose  |

Neither vaccine contain eggs, gelatin, latex, or preservative

## AZD1222

AZD1222 is Astra Zeneca’s replication defective simian (chimpanzee) adenovirus vaccine containing a full-length spike protein and a leading tissue plasminogen activator (tPA) sequence that produces both a cellular and humoral response to the SARS-CoV-2 virus.<sup>32</sup> The tPA component has been demonstrated to enhance immunogenicity in another ChAdOx1 vectored CoV vaccine (ChAdOx1 MERS).<sup>32</sup> Clinical trials consist of 2 phase 1/2 trial ([NCT04324606](#) & [NCT04568031](#); active, not recruiting), a phase 2 trial ([NCT0444674](#); recruiting), a phase 2/3 trial ([NCT04400838](#); recruiting), 4 phase 3 trials ([NCT04540393](#) [suspended], [ISRCTN89951424](#) not recruiting; and [NCT04516746](#) & [NCT04536051](#) recruiting) and are being completed in various ages and populations. Summaries of the published phase 1/2 trial, interim phase 2 UK trial, and the phase 3 U.S. trial are in [Appendix C](#). The UK phase 1/2 trial started enrolling patients in April of 2020 in the UK through May of 2020 and results were published in August. The Japan phase 1/2 trial targets enrollment of 256 patients ≥18 years of age. The phase 2 trial was initiated in June in South Africa and is recruiting 2,000 patients with and without HIV infection. The phase 2/3 trial began in the UK in May of 2020 and is estimating enrollment of 12,330 patients including ages 5 to 12 years and ≥ 18 years. A phase 3 trial currently enrolling patients is being conducted in Brazil in healthcare workers or other adults at high risk of contracting infections and is projected to be completed in 10,300

patients. On December 30, 2020, the UK Medicines & Healthcare Products Agency (MHRA) **approved** AZD1222 for use in patients  $\geq 18$  years of age at 2 standard doses separated by 4 to 12 weeks. India **approved** use on January 3, 2021 followed by **Mexico** on January 4, 2021.

## Efficacy

Data published in the phase 1/2 trial in adults 18-55 years of age indicate ChAdOx1 nCoV-19  $5 \times 10^{10}$  virus particles (0.5 mL intramuscularly) produced a humoral response as indicated by anti-spike IgG and a cellular response by spike-specific T-cell response.<sup>32</sup> Boosting with a second dose at day 29 occurred in a small number of patients ( $n = 10$ ) and produced an increase in anti-spike IgG. MNA<sub>80</sub> is defined as titers inducing 80% virus neutralization. MNA<sub>80</sub> was achieved in 32/35 (91%) patients after a single dose and 9/9 after a booster dose (100%). Pending phase 3 and 2/3 trials are generally focusing on a 2-dose approach.

Interim (phase 2) data published from the phase 2/3 UK trial evaluated a ChAdOx1 standard dose ( $3.5\text{-}6.5 \times 10^{10}$  vp) or low dose ( $2.2 \times 10^{10}$  vp) intramuscular injection in 1 or 2 doses (separated by 28 days) in 3 adult age groups (18-55, 56-69,  $\geq 70$  y) and found cellular and humoral activity in all groups as indicated by T-cell response (Interferon-gamma ELISpot), SARS-CoV-2 live virus microneutralization PHE MNA80, and IgG response by ELISA. Fourteen days after a second dose, 99% of participants mounted neutralizing antibody responses in the standard dose group.<sup>33</sup>

In a **press release** published on November 23, AstraZeneca announced top line efficacy data in the UK and Brazil trials. The primary endpoint of preventing symptomatic COVID-19 was demonstrated in 62% and 90% of 2 different dosing regimens: a half dose followed by a full dose or 2 full doses, respectively resulting in an average efficacy of 70%.<sup>34</sup> No hospitalizations or severe cases of disease were noted in patients who received vaccine. The subsequent interim analysis of 4 phase 3 trials was published on December 8, 2020 and included results from **ISRCTN89951424**, **NCT04324606**, **NCT04400838**, **NCT04444674** completed in Brazil, the UK, and South Africa.<sup>35</sup> Participants received 2 doses: standard or low dose AZD1222 followed by standard dose AZD1222 in the treatment arm, vs. saline or meningococcal vaccine in the placebo arm (see specific protocols for details). When all dosing schemas were included, VE as measured by the primary endpoint (symptomatic COVID-19  $\geq 15$  days after the second dose) was 70.4% (95 CI, 54.8-80.6). Two standard doses produced a vaccine efficacy of 62.1% (95% CI, 41-75.7) and a low dose followed by a standard dose produced a vaccine efficacy of 90% (95% CI, 67.4- 97).<sup>35</sup>

## Safety

No serious adverse events were reported in the phase 1/2 trial. Local and systemic reactions were reported in the ChAdOx1 nCoV-19 group and were reduced in patients instructed/allowed to use paracetamol prophylactically (1 g every 6 h for 24 h) including but not limited to pain, feeling feverish, chills, muscle ache, headache, and malaise. Immunogenicity in patients advised to take paracetamol prophylactically was similar to those who were not advised to do so; however, these data were not reported.<sup>32</sup>

Interim (phase 2) data published from the phase 2/3 UK trial reported 13 serious adverse drug events at time of publication; however, none were attributed to the vaccine. The most common local adverse events were pain and tenderness at the injection site with the most common systemic adverse events of fatigue, headache, feverishness, and

myalgia. Decreased reactogenicity was observed in older adults. Refer to pages 16-31 of the **supplement** for detailed information regarding local and systemic effects.<sup>33</sup>

The interim analysis of 4 phase 3 trials with results from **ISRCTN89951424**, **NCT04324606**, **NCT04400838**, **NCT04444674** completed in Brazil, the UK, and South Africa reported serious adverse events occurred in 79 AZD1222 vaccine recipients. One case of transverse myelitis was reported following a booster dose and was thought to be possibly related to vaccination. An unmasked patient experienced a high fever (> 40°C) after a first dose, but not a second. One additional case of transverse myelitis was determined likely unrelated to vaccine administration. Four non-COVID-19-related deaths (1 in AZD1222 group) were all considered to be unrelated to the vaccine.<sup>35</sup>

## **JNJ-78436735**

JNJ-78436735 is Janssen's non-replicating adenovirus 26 (Ad26) based vaccine expressing a stabilized pre-fusion full-length spike protein that produces both a cellular and humoral response to the SARS-CoV-2 virus.<sup>36</sup> Clinical trials consists of a phase 1 trial (**NCT04509947**; active, recruiting), a phase 1/2a trial (**NCT04436276**; active, recruiting), a phase 2 trial (**NCT04535453**; active, recruiting) and 2 phase 3 trials (**NCT04505722**; recruiting; **NCT04614948**; recruiting). Summaries of the prepublication manuscript of the phase 1/2a trial and the description of the phase 3 trials are in **Appendix C**. The phase 1/2a trial started enrolling patients in June of 2020 and interim results were released in pre-publication form in September.<sup>36</sup> The ENSEMBLE phase 3 trial was initiated in September and J&J anticipates interim data will be available by the end of January 2021.

### **Efficacy and safety: Phase 1/2a**

Interim data was presented in a pre-publication manuscript of a multicenter, randomized, double-blind, placebo-controlled phase 1/2a trial and describes interim safety and immunogenicity following a single dose in two age cohorts (18-55 yo and ≥65 yo). These preliminary data indicate a single dose of JNJ- 78436735,  $5 \times 10^{10}$  virus particles or  $1 \times 10^{11}$  virus particles produced a humoral response as demonstrated by spike-specific ELISA geometric mean titers (GMT) and presence of neutralizing titers by wild-type virus neutralization assay (wtVNA) GMT. GMT in human convalescent plasma overlapped in the 95% CI range of the 2 aforementioned humoral response tests. Cellular response was demonstrated through Th1 cytokine producing CD4+ T cell (S-specific) response (cohort 1a: 80%; cohort 3: 83%) and CD8+ T cell (S-specific) response (varied by age group and dose: 33-64%). Regarding safety, local adverse events were reported in 58% of patients in cohort 1 (18-55 yo) and 27% of patients in cohort 3 (≥ 65 yo). The most common local adverse effect was injection site reaction and most frequent systemic reactions were headache, fatigue, and myalgia. Fever was reported in 64% of cohort 1 patients and 36% of cohort 3 patients. Assessment for vaccine associated enhanced respiratory disease (VAERD) was completed by measuring CD4+ Th1 and Th2 responses to the vaccine evaluating for Th2 skewed response. One participant in the 1a cohort had a Th2 response and the Th1/Th2 ratio indicated it was a Th-1 skewed response; hence, VAERD risk is expected to be low.<sup>36</sup> Additional detail regarding safety and efficacy is expected when the full results are published.

### **Phase 3**

The phase 3 ENSEMBLE trial will focus on a single dose approach using  $5 \times 10^{10}$  virus particles in adult patients (goal n = 60,000). Primary and secondary outcome measures are listed in [Appendix D](#). Johnson and Johnson announced in November 2020 the initiation of the 2-dose regimen ENSEMBLE 2 trial. The ENSEMBLE 2 trial will run in parallel to the ENSEMBLE trial and is expected to enroll 30,000 patients worldwide.

## NVX-CoV2373

NVX-CoV2373 is a recombinant protein nanoparticle vaccine, consisting of purified protein antigen—specifically, the full-length SARS-CoV-2 spike glycoprotein, synthesized using Novavax' Sf9/BV insect cell platform—and Matrix-M1 adjuvant.<sup>37</sup> The phase 1 trial ([NCT04368988](#)) was comprised of 131 healthy adults, aged 18 to 84 years, who received rSARS-CoV-2 in 1 of 2 doses (5 mcg or 25 mcg), either with (n = 83) or without (n = 25) Matrix-M1 adjuvant, or placebo (n = 23). Vaccination consisted of 2 intramuscular injections, administered 21 days apart. Primary outcomes in the phase 1 trial included reactogenicity and IgG anti-spike protein response; secondary outcomes included wild-type virus neutralization and T-cell responses.<sup>37</sup> Currently, only phase 1 clinical trial data have been published (summarized in [Appendix E](#)); publication of results from the phase 1/2 trial continuation in the U.S. and Australia ([NCT04368988](#)) are still pending.

### Efficacy and safety: Phase 1

Phase 1 clinical trial data<sup>37</sup> (summarized in [Appendix E](#)), demonstrated that NVX-CoV2373 elicits a Th1-dominant response and produces spike-specific IgG and neutralizing antibodies in levels exceeding those found in COVID-19 convalescent serum. The addition of Matrix-M1 adjuvant was found to produce a dose-sparing effect, with similar magnitudes of response seen with administration of 5 mcg and 25 mcg doses of rSARS-CoV-2. Specifically, the 2-dose 5 mcg adjuvanted regimen produced 63,160 EU/mL of anti-spike IgG (vs. 8,344 EU/mL [mean, overall] and 53,391 EU/mL [mean, hospitalized patients] of anti-spike IgG found in human convalescent serum) and a GMT neutralizing antibody response of 3,906 as compared to 984 (overall mean) in human convalescent plasma.

Reactogenicity was absent or mild in most patients and no serious adverse events were reported. Localized adverse events consisted primarily of pain and tenderness and the most common systemic adverse events were fatigue, headache, and myalgia. Only 1 participant experienced a fever. The mean duration of reactogenicity events was 2 days or less after both first and second vaccinations.

### Phase 3

On September 24, 2020, Novavax **announced** that it launched its phase 3 trial for NVX-CoV2373 in the UK. The trial will enroll up to 10,000 healthy adults between the ages of 18 and 84 years, both “with and without relevant comorbidities.” Participants will be randomized to receive 2 intramuscular injections, 21 days apart, of either the vaccine (5 mcg protein antigen + 50 mcg Matrix-M adjuvant) or placebo. Up to 400 participants will also receive a licensed seasonal influenza vaccine as part of a co-administration sub-study. The primary efficacy analysis will be an event-driven analysis based on the number of participants with symptomatic or moderate to severe COVID-19, and an interim analysis will be performed when 67% of the desired number of cases is reached. The primary endpoints will be first occurrence of either

symptomatic COVID-19 OR symptomatic moderate or severe COVID-19, with an onset of at least 7 days after the second dose in participants not previously infected with SARS-CoV-2.<sup>38</sup> The protocol for this phase 3 study was published October 27, 2020.

On October 27, 2020, Novavax provided an **update** on the UK phase 3 trial. The trial currently has 5,500 individuals enrolled and has expanded its target enrollment from 10,000 to 15,000 participants. The increased enrollment is expected to “facilitate assessment of safety and efficacy in a shorter time period.” Novavax predicts full enrollment by the end of November with interim data available in early Q1 2021. Additionally, the update indicated that phase 3 trials in the U.S. and Mexico are expected to begin by the end of November.<sup>39</sup>

On December 28, 2020, Novavax announced the initiation of PREVENT-19 (PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19, **NCT04611802**), the phase 3 study in the United States and Mexico to evaluate the NVX-CoV2373 vaccine for safety, efficacy and immunogenicity. PREVENT-19 is a randomized, placebo-controlled, observer-blinded study of up to 30,000 subjects aged 18 years and older. Two thirds of study volunteers will be assigned to receive intramuscular injections of the study vaccine to be administered 21 days apart. The other one third of participants will receive placebo. The primary endpoint is the prevention of PCR-confirmed, symptomatic COVID-19 with a secondary endpoint of the prevention of PCR-confirmed symptomatic moderate or severe COVID-19 to be assessed at least 7 days after the second study vaccination in patients who have not been previously infected by SARS-CoV-2. Participants will be followed for 24 months after the second injection.<sup>40</sup>

## References

1. Fact sheet: Explaining operation warp speed. HHS website. <https://www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html>. Published June 16, 2020. Accessed September 16, 2020.
2. Slaoui M, Hepburn M. Developing safe and effective Covid vaccines – Operation Warp Speed’s strategy and approach. *N Engl J Med*. Published online August 26, 2020. *N Engl J Med*. doi: 10.1056/NEJMp2027405.
3. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. *N Engl J Med*. 2020;382(21):1969-1973.
4. Development and licensure of vaccines to prevent COVID-19: Guidance for industry. Food and Drug Administration website. <https://www.fda.gov/media/139638/download>. Published June 2020. Accessed September 16, 2020.
5. Emergency use authorization for vaccines to prevent COVID-19: Guidance for industry. Food and Drug Administration website. <https://www.fda.gov/media/142749/download>. Published October 2020. Accessed October 7, 2020.
6. Shah A, Marks PW, Hahn SM. Unwavering regulatory safeguards for COVID-19 vaccines. *JAMA*. 2020;324(10):931-932.
7. Mullard A. COVID-19 vaccine development pipeline gears up. *Lancet*. 2020;395(10239):1751-1752.
8. Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine – United States, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:1857-1859.
9. Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine – United States, December 2020. *MMWR Morb Mortal Wkly Rep*. 2021;69:1657-1660.
10. Wang F, Kream RM, Stefano GB. An evidence-based perspective on mRNA-SARS-CoV-2 vaccine development. *Med Sci Monit*. 2020;26:e924700.
11. Heaton PM. The Covid-19 vaccine-development multiverse. *N Engl J Med*. 2020;383(20):1986-1988.

12. Dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 COVID-19 vaccine in adults aged 18 years and older. ClinicalTrials.gov website. <https://www.clinicaltrials.gov/ct2/show/NCT04405076?term=NCT04405076&draw=2&rank=1>. Published May 28,2020. Updated July 10, 2020. Accessed September 23, 2020.
13. Baden LR, El Sahly HM, Essink B, et al for the COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New Engl J Med*. Published online ahead of print December 30, 2020. doi: 10.1056/NEJMoa2035389.
14. Moderna clinical study protocol. Moderna website. <https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf>. Published August 20, 2020. Accessed September 23, 2020.
15. Jackson LA, Anderson EJ, Roupheal NG et al for the mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 – Preliminary Report. *N Engl J Med*. 2020;383(20):1920-1931.
16. Anderson EJ, Roupheal NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N Engl J Med*. 2020;383(25):2427-2438.
17. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020. FDA Briefing Document. Moderna COVID-19 vaccine. FDA website. <https://www.fda.gov/media/144434/download>. Published December 15, 2020. Accessed December 15, 2020.
18. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020. Sponsor Briefing Document. Moderna COVID-19 vaccine. FDA website. <https://www.fda.gov/media/144452/download>. Published December 15, 2020. Accessed December 15, 2020.
19. Vogel AB, Kanevsky I, Che Y, et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. Published online ahead of print on September 8, 2020. Available online at <https://doi.org/10.1101/2020.09.08.280818>.
20. A trial investigating the safety and effects of four BNT162 vaccines against COVID-2019 in healthy adults. U.S. National Library of Medicine (ClinicalTrials.gov) website. <https://clinicaltrials.gov/ct2/show/NCT04380701?term=BNT162b2&draw=2&rank=1>. Published May 8, 2020. Updated September 11, 2020. Accessed September 15,2020.
21. Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy adults. U.S. National Library of Medicine (ClinicalTrials.gov) website. <https://clinicaltrials.gov/ct2/show/NCT04368728?term=BNT162b2&draw=2&rank=2>. Published April 30, 3030. Updated September 4, 2020. Accessed September 15,2020.
22. Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. *N Engl J Med*. Published online ahead of print on October 14, 2020. doi: 10.1056/NEJMoa2027906
23. Pfizer. Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial. Pfizer website. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19>. Published September 12, 2020. Accessed September 15, 2020.
24. Pfizer. Our progress in developing a potential COVID-19 vaccine. Pfizer website. <https://www.pfizer.com/science/coronavirus/vaccine>. Updated October 26, 2020. Accessed October 27, 2020.
25. Pfizer. A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals: Clinical Protocol. Pfizer website. <https://www.pfizer.com/clinicalprotocol>. Accessed November 18, 2020.
26. Polack FP, Thomas SJ, Kitchin N, et al for the C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. Published online ahead of print December 10, 2020. doi: 10.1056/NEJMoa2034577.
27. U.S. Food and Drug Administration. Vaccine and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document – FDA. FDA website. <https://www.fda.gov/media/144245/download>. Published December 8, 2020. Accessed December 8, 2020.
28. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. *MMWR Morb Mortal Wkly Rep*. Published online ahead of print January 6, 2021. <http://dx.doi.org/10.15585/mmwr.mm7002e1>.

29. Centers for Disease Control and Prevention. Interim considerations: Preparing for the potential management of anaphylaxis at COVID-19 vaccination sites. CDC website. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxis-management.html>. Updated December 31, 2020. Accessed January 6, 2021.
30. Centers for Disease Control and Prevention. Clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. CDC website. <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>. Updated January 6, 2021. Accessed January 6, 2021.
31. ACAAI provides further guidance on risk of allergic reactions to mRNA COVID-19 vaccines. ACAAI website. <https://college.acai.org/acai-guidance-on-risk-of-allergic-reactions-to-mrna-covid-19-vaccines/> Updated December 21, 2021. Accessed January 6, 2021.
32. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. Published online ahead of print July 20, 2020. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4).
33. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. *Lancet*. Published online ahead of print November 9, 2020. [https://doi.org/10.1016/S0140-6736\(20\)32466-1](https://doi.org/10.1016/S0140-6736(20)32466-1).
34. AstraZeneca. AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. AstraZeneca website. <https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html>. Published November 23, 2020. Accessed December 9, 2020.
35. Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. *Lancet*. Published online ahead of print December 8, 2020. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32661-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext)
36. Sadoff J, Le Gars M, Shukarev G, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. Published online ahead of print on September 25, 2020 at <https://doi.org/10.1101/2020.09.23.20199604>.
37. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. *New Engl J Med*. Published online ahead of print September 2, 2020. doi: 10.1056/NEJMoa2026920. Accessed October 5, 2020.
38. Novavax. Novavax initiates phase 3 efficacy trial of COVID-19 vaccine in the United Kingdom. Novavax website. <https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united>. Published September 24, 2020. Accessed October 5, 2020.
39. Novavax. Novavax provides phase 3 COVID-19 vaccine clinical development update. Novavax website. <https://ir.novavax.com/news-releases/news-release-details/novavax-provides-phase-3-covid-19-vaccine-clinical-development>. Published October 27, 2020. Accessed October 27, 2020.
40. Novavax. Novavax announces initiation of PREVENT-19 pivotal phase 3 efficacy trial of COVID-19 vaccine in the United States and Mexico. Published December 28, 2020. Accessed January 5, 2020.



## Appendix A – mRNA-1273 trials

| Study Design   | N  | Patient Selection  | Treatment Interventions   | Main results   |  |
|--|----|--|---|--|--|
|  |    |  |   | Immunogenicity   | Discontinuation and Safety   |
| <p>Jackson LA, et al.</p> <p>mRNA-1273 study group</p> <p>Phase 1, dose-escalation, open-label clinical trial</p> <p>Interim analysis through day 57 (28 d after second dose of vaccine)</p> | 45 | <p>Healthy adults 18 to 55 y</p> <p>Baseline characteristics</p> <ul style="list-style-type: none"> <li>Male, n = 22 (49%)</li> <li>Age, mean (SD): 33.0 y (8.5)</li> <li>White, n = 40 (89%)</li> <li>BMI, mean (SD): 25.3 (3.2)</li> </ul> | <p><b>Intervention group</b></p> <p>2 injections of mRNA-1273 given 28 d apart at 3 different dose levels:</p> <ul style="list-style-type: none"> <li>25 mcg (n = 15)</li> <li>100 mcg (n = 15)</li> <li>250 mcg (n = 15)</li> </ul> <p>Vaccine administered as a 0.5-mL injection in deltoid muscle on days 1 and 29</p> <p><b>Control group</b></p> <p>Convalescent serum specimens (n = 38 samples)</p> <ul style="list-style-type: none"> <li>Mild infection (63%)</li> <li>Moderate infection (22%)</li> <li>Severe infection (15%)</li> </ul> | <p><b>SARS-CoV-2 antibody response</b></p> <p>Seroconversion, measured by ELISA, defined as a 4-factor or more increase in antibody titer over baseline. All patients achieved seroconversion by day 15.</p> <p><b>Anti-S-2P ELISA mean GMTs (95% CI) at day 57</b></p> <ul style="list-style-type: none"> <li>25-mcg group: 299,751 (206,071 – 436,020)</li> <li>100-mcg group: 782,719 (619,310 – 989,244)</li> <li>250-mcg group: 1,192,154 (924,878 – 1,536,669)</li> <li>Convalescent serum: 142,140 (81,543 – 247,768)</li> </ul> <p><b>Anti-receptor-binding domain GMT (95% CI) at day 57</b></p> <ul style="list-style-type: none"> <li>25-mcg group: 183,652 (122,763 – 274,741)</li> <li>100-mcg group: 371,271 (266,721-516,804)</li> <li>250-mcg group: 582,259 (404,019 – 839,134)</li> <li>Convalescent serum: 37,857 (19,528 – 73,391)</li> </ul> <p><b>Pseudovirus neutralization assay (PsVNA)</b></p> <ul style="list-style-type: none"> <li>No participant had detectable PsVNA responses before vaccination</li> <li>&lt; 50% had a PsVNA response after first dose</li> <li>100% had a PsVNA response after second dose with higher responses seen in the 100-mcg and 250-mcg group vs. the 25-mcg group at day 43</li> </ul> <p><b>Live SARS-CoV-2 PRNT</b></p> <ul style="list-style-type: none"> <li>Before vaccination, no participant had detectable 80% live-virus neutralization activity</li> <li>At day 43, all participants had neutralizing activity capable of reducing infectivity by 80%</li> </ul> <p><b>SARS-CoV-2 T-cell responses</b> (data available only for 25-mcg and 100-mcg doses)</p> <ul style="list-style-type: none"> <li>Both doses elicited CD4 T-cell responses – strongly biased toward expression of Th1 cytokines, with minimal type 2 helper T-cell cytokine expression</li> <li>CD8 T-cell responses were detected at low levels after the second dose in the 100-mcg group</li> </ul> | <p>Discontinuations due to safety (n = 1)</p> <ul style="list-style-type: none"> <li>25 mcg group - discontinued due to transient urticaria, judged to be related to the first vaccination</li> </ul> <p>Incidence of solicited systemic AEs, first dose</p> <ul style="list-style-type: none"> <li>25-mcg group, n = 5 (33%)</li> <li>100-mcg group, n = 10 (67%)</li> <li>250-mcg group, n = 8 (53%)</li> </ul> <p>Incidence of solicited systemic AEs, second dose</p> <ul style="list-style-type: none"> <li>25-mcg group, n = 7 (54%)</li> <li>100-mcg group, n = 15 (100%)</li> <li>250-mcg group, n = 14 (100%); 3 (21%) reported ≥ 1 severe AE</li> </ul> <p>Solicited systemic and local AEs with incidence ≥ 50%</p> <ul style="list-style-type: none"> <li>Fatigue, chills, headache, myalgia, and pain at the injection site</li> </ul> <p>No patterns of concern for unsolicited AEs or for clinical laboratory values of grade 2 or higher</p> |

| Study Design  | N      | Patient Selection  | Treatment Interventions   | Main results  |   |
|---|--------|--|---|---|---|
|   |        |  |   | Immunogenicity  | Discontinuation and Safety  |
| <p>Anderson EJ, et al.</p> <p>mRNA-1273 study group</p> <p>Phase 1, dose-escalation, open-label clinical trial</p> <p>Interim analysis through day 57 (28 d after second dose of vaccine)</p> | 40     | <p>Healthy adults aged ≥ 56 y old</p> <p>Baseline characteristics</p> <ul style="list-style-type: none"> <li>Male, n = 19 (48%)</li> <li>Age, mean: 68.7 y</li> <li>White, n = 39 (98%)</li> <li>BMI, mean (SD): 25 (3)</li> </ul>                                   | <p><b>Intervention group</b></p> <p>2 injections of mRNA-1273 given 28 d apart at 3 different dose levels:</p> <p>56-70 y old cohort</p> <ul style="list-style-type: none"> <li>25 mcg (n = 10)</li> <li>100 mcg (n = 10)</li> </ul> <p>≥71 y old cohort</p> <ul style="list-style-type: none"> <li>25 mcg (n = 10)</li> <li>100 mcg (n = 10)</li> </ul> <p>Vaccine administered as a 0.5-mL injection in deltoid muscle on days 1 and 29</p> <p><b>Control group</b></p> <p>Convalescent serum specimens (n = 38 samples)</p> <ul style="list-style-type: none"> <li>Mild infection (63%)</li> <li>Moderate infection (22%)</li> <li>Severe infection (15%)</li> </ul> | <p><b>Binding antibody response</b></p> <p><b>Anti-S-2P ELISA mean GMTs (95% CI) at day 57</b></p> <ul style="list-style-type: none"> <li>25-mcg group, 56-70 y: 323,945 (182,202-575,958)</li> <li>25-mcg group, ≥ 71 y: 1,128,391 (636,087-2,001,717)</li> <li>100-mcg group, 56-70 y: 1,183,066 (379,698-3,686,201)</li> <li>100-mcg group, ≥ 71 y: 3,638,522 (1,316,233-10,058,130)</li> <li>Convalescent serum: 138,901 (82,876-232,799)</li> </ul> <p><b>Neutralizing antibody response</b></p> <ul style="list-style-type: none"> <li>Measured by pseudovirus, PRNT, nLuc HTNA, and FRNT-mNG</li> <li>Pseudovirus neutralization: Age-independent responses induced as early as 7 d after second dose</li> <li>nLuc HTNA and FRNT-mNG: Age-independent responses induced by 14 d after second dose</li> <li>PRNT: Age-dependent responses induced by 14 d after second dose with higher response in 56-70 y cohort</li> </ul> <p><b>SARS-CoV-2 T-cell responses</b></p> <ul style="list-style-type: none"> <li>100-mcg group elicited CD4 T-cell responses – strongly biased toward expression of Th1 cytokines, with minimal type 2 helper T-cell cytokine expression – in both age groups</li> <li>25-mcg group only elicited a T-cell response in the 56-70 y cohort</li> </ul> | <p>Most common solicited AEs:</p> <ul style="list-style-type: none"> <li>Headache</li> <li>Fatigue</li> <li>Myalgia</li> <li>Chills</li> <li>Injection-site pain</li> </ul> <p>All 10 solicited local AEs that were classified as moderate occurred after the second dose</p> <p>All but 2 systemic AEs classified as moderate occurred after the second dose</p> |
| <p>Phase 3 trial – ongoing</p> <p>COVE trial</p> <p>(NCT04470427)</p> <p>2 interim analysis planned</p>   | 30,000 | <p>For full inclusion/exclusion criteria, see <b>clinical trial protocol</b></p> <p><b>Inclusion</b></p> <ul style="list-style-type: none"> <li>≥ 18 y</li> <li>Healthy adults or adults with pre-existing medical conditions who are in stable condition</li> </ul> | <p><b>Intervention</b></p> <ul style="list-style-type: none"> <li>mRNA-1273 – 100 mcg injection given on Day 1 and on Day 29</li> </ul> <p><b>Control</b></p> <ul style="list-style-type: none"> <li>Placebo – 0.9% sodium chloride injection</li> </ul>  | <p><b>Primary outcome</b></p> <ul style="list-style-type: none"> <li>Number of participants with a first occurrence of COVID-19 starting 14 days after second dose of mRNA-1273 [time frame: 29 d up to 2 y after second dose] <ul style="list-style-type: none"> <li>Interim analysis, per-protocol (n = 27,817); VE: 94.5% (95% CI, 86.5-97.8%)</li> <li>Primary analysis, per-protocol (n = 28,207); VE: 94.1% (95% CI, 89.3-96.8%)</li> </ul> </li> </ul> <p><b>Secondary outcome</b></p> <ul style="list-style-type: none"> <li>Cases of severe COVID-19 based on adjudication committee assessment starting 14 days after the second injection <ul style="list-style-type: none"> <li>Primary analysis (n = 28,207): VE: 100% (95% CI, not estimable -100%)</li> </ul> </li> </ul> <p><b>Adverse events</b></p> <ul style="list-style-type: none"> <li>Most common local and systemic solicited events occurring up to 7 days after injection: Injection-site pain (91.6%), fatigue (68.5%), headache (63%), muscle pain (59.6%), joint pain (44.8%), chills (43.4%)</li> </ul>   |   |

Abbreviations: AE = adverse event; CI = confidence intervals; FRNT-mNG = focus reduction neutralization test mNeonGreen; GMT = geometric mean titers; nLuc HTNA = nanoluciferase high-throughput neutralization assay; PRNT = plaque reduction neutralization test; SD = standard deviation

## Appendix B – BNT162b2 trials

| Study Design  | N   | Patient Selection  | Treatment Interventions  | Main results  |  |
|---|-----|--|--|---|--|
|   |     |  |  | Immunogenicity  | Discontinuation and Safety   |
| <p>Walsh EE, et al.</p> <p>Phase 1, randomized, placebo-controlled, observer-blinded, dose-escalation study</p> <p>(NCT04368728)</p> <p><i>Note: The data set presented here guided Pfizer and BioNTech's decision to advance BNT162b2 at the 30-mcg dose level into the Phase 2/3, global safety and efficacy evaluation</i></p> | 195 | <p>For full inclusion and exclusion criteria, see <a href="#">NCT04368728</a></p> <p>Inclusion</p> <ul style="list-style-type: none"> <li>Healthy adults age 18-55 or 65-85</li> </ul> | <p><b>Study Design</b></p> <p>13 groups, 15 participants each (n = 195):</p> <ul style="list-style-type: none"> <li>Two vaccine candidate "arms": BNT162b1 and BNT162b2</li> <li>Each arm further subdivided by age range (18-55 and 65-85) and vaccine dose (10 mcg, 20 mcg, or 30 mcg)</li> <li>Participants received two 0.5-mL injections to the deltoid of either BNT162b1, BNT162b, or placebo, 21 d apart</li> <li>One additional group of 18-55 y participants randomized to receive 1 dose of 100 mcg vs. placebo</li> <li>In each of the 13 groups, n=12 received vaccine and n=3 received placebo</li> </ul> <p><i>Note: Participants were primarily white (67 – 100%) and non-Hispanic (89 – 100%), depending on intervention group; there was a higher proportion of females than males in the 65-85 y age groups</i></p> | <p>Immunogenicity assessments:</p> <ul style="list-style-type: none"> <li>RBD- or S1-binding IgG direct Luminex immunoassay and SARS-CoV-2 serum neutralization assay</li> <li>Sera obtained/assessed—prior to vaccine or placebo administration—on days 1 (dose 1), 21 (dose 2), 28, and 35</li> <li>Immunogenicity data from a human convalescent serum (HCS) panel served as benchmark <ul style="list-style-type: none"> <li>n = 38 donors, age 18-83 y (median age, 42.5 y), who had recovered from SARS-CoV-2 infection</li> </ul> </li> </ul> <p>Note: Immunogenicity responses for 30 mcg dose (selected to move into phase 2/3 study) reported out here. See Figure 4 in NEJM for full report out of dose-dependent immunogenic responses</p> <p>GMCs (U/mL) of recombinant S1-binding IgG</p> <ul style="list-style-type: none"> <li>Placebo: 0.9; HCS: 631</li> <li>BNT162b1 (18 – 55 y vs. 65 – 85 y) <ul style="list-style-type: none"> <li>D0: 0.8 vs. 0.7</li> <li>D21: 853 vs. 86</li> <li>D28: 23,516 vs. 6,580</li> <li>D35: 13,940 vs. 4,798</li> </ul> </li> <li>BNT162b2 (18 – 55 y vs. 65 – 85 y) <ul style="list-style-type: none"> <li>D0: 0.6 vs. 0.6</li> <li>D21: 1,265 vs. 329</li> <li>D28: 9,136 vs. 7,985</li> <li>D35: 8,147 vs. 6,014</li> </ul> </li> </ul> <p>50% SARS-CoV-2-neutralizing GMT</p> <ul style="list-style-type: none"> <li>Placebo: 10; HCS: 94</li> <li>BNT162b1 (18 – 55 y vs. 65 – 85 y) <ul style="list-style-type: none"> <li>D0: 10 vs. 10</li> <li>D21: 29 vs. 12</li> <li>D28: 267 vs. 101</li> <li>D35: 437 vs. 105</li> </ul> </li> <li>BNT162b2 (18 – 55 y vs. 65 – 85 y) <ul style="list-style-type: none"> <li>D0: 10 vs. 10</li> <li>D21: 14 vs. 12</li> <li>D28: 361 vs. 149</li> <li>D35: 163 vs. 206</li> </ul> </li> </ul> | <p><b>Local events</b></p> <ul style="list-style-type: none"> <li>Primarily mild to moderate in severity</li> <li>Pain at injection site most common; percentage reported with 30 mcg dose are as follows (dose 1 vs. dose 2): <ul style="list-style-type: none"> <li>BNT162b1 (18-55y): 100% vs. 100%</li> <li>BNT162b1 (65-85y): 92% vs. 75%</li> <li>BNT162b2 (18-55y): 92% vs. 83%</li> <li>BNT162b2 (65-85y): 75% vs. 67%</li> </ul> </li> <li>8% of participants age 18-55 reported redness with dose 1 of 30 mcg BNT162b2; no other reports of redness or swelling reported with the 30 mcg dose (more common with the BNT162b1 candidate)</li> </ul> <p><b>Systemic events</b></p> <p>BNT162b1</p> <ul style="list-style-type: none"> <li>18-55 y: frequently reported mild-moderate fever and chills, with 75% reporting a fever <math>\geq 38^{\circ}\text{C}</math> after dose 2 of 30 mcg</li> <li>65-85 y: systemic events milder as compared to younger group (i.e. only 33% reported fever after dose 2), though many reported fatigue, headache after dose 1 or 2</li> </ul> <p>BNT162b2</p> <ul style="list-style-type: none"> <li>Systemic events were milder for BNT162b2 vs. BNT162b1 <ul style="list-style-type: none"> <li>Only 17% of 18-55 y and 8% of 65-85 y experienced fever with dose 2 of 30 mcg BNT162b2</li> </ul> </li> <li>Severe systemic events (i.e. fatigue, headache, chills, muscle/joint pain) reported in a small number 18-55 y; none in 65-85 y</li> </ul> |

| Study Design                     | N      | Patient Selection  | Treatment Interventions  | Main results  |                            |
|----------------------------------|--------|--|--|---|----------------------------|
|                                  |        |  |  | Immunogenicity  | Discontinuation and Safety |
| Phase 2/3 trial<br>(NCT04368728) | 43,661 | <p>For full inclusion and exclusion criteria, see <b>NCT04368728</b></p> <p><b>Inclusion</b></p> <ul style="list-style-type: none"> <li>Healthy individuals aged ≥12 y, stratified: <ul style="list-style-type: none"> <li>12-15 y</li> <li>16-55 y</li> <li>&gt;55 y</li> </ul> </li> </ul> <p><b>Exclusion</b></p> <ul style="list-style-type: none"> <li>Immunocompromised</li> <li>Prior coronavirus vaccination</li> <li>Receipt of blood/plasma products or immunoglobulin in 60 days prior to study or planned during study</li> </ul> <p><b>Demographics of main safety population (n = 37,706)</b></p> <ul style="list-style-type: none"> <li>Male: 50.6%</li> <li>Median age at vaccination: 52 (range: 16-91)</li> <li>White: 82.9%</li> <li>Black: 9.3%</li> <li>Hispanic/Latino: 28%</li> <li>Obese: 35%</li> </ul> | 2 doses of BNT162b2 (30 mcg) or placebo, administered 21 d apart | <p><b>Primary efficacy endpoints</b></p> <p><b>First:</b> Efficacy of BNT162b2 against confirmed COVID-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose (n = 36,523)</p> <ul style="list-style-type: none"> <li>n = 170 cases of COVID-19 (n = 162 in placebo group, n = 8 in BNT162b2 group)</li> <li>VE: 95% (95% credible interval, 90.3-97.6)</li> </ul> <p><b>Second:</b> Efficacy of BNT162b2 against confirmed COVID-19 with onset at least 7 days after the second dose in participants with and without prior SARS-CoV-2 infection (n = 40,137)</p> <ul style="list-style-type: none"> <li>n = 178 cases of COVID-19 (n = 169 in placebo group, n = 9 in BNT162b2 group)</li> <li>VE: 94.6% (95% credible interval, 89.9-97.3)</li> </ul> <p><b>Secondary efficacy endpoint</b></p> <p>Severe COVID-19 disease: 10 cases observed after the first dose (1 vaccine; 9 placebo)</p> <p><b>Safety efficacy endpoints</b></p> <p>Reactogenicity subset (n = 8,183) – Vaccine recipient reported events</p> <ul style="list-style-type: none"> <li>Mild to moderate pain at injection site most common local reaction in ≤55 y (83% dose 1, 78% dose 2) and &gt;55 y (71% dose 1, 66% dose 2)</li> <li>Most common systemic reactions were fatigue and headache. More common in the ≤ 55 y cohort (59% and 52% after dose 2) vs. &gt; 55 y cohort (51% and 39% after dose 2). In all age cohorts, frequency and severity higher after dose 2.</li> <li>Severe (grade 3) systemic events of fatigue and headache reported in 3.8% and 2.0% of recipients, respectively.</li> <li>Fever (temp ≥ 38°C) reported after second dose in 16% and 11% of those ≤ 55 y and &gt; 55 y, respectively.</li> <li>Fever (temp 38.9-40°C) reported in 0.2% after first dose (vs. 0.1% in placebo group) and 0.8% after second dose (vs. 0.1% in placebo).</li> <li>Younger cohort more likely to take use antipyretic or pain medication (28% after first dose; 45% after dose 2) vs. older cohort (20% after dose 1; 38% after dose 2)</li> </ul> <p><b>Main safety population (n = 37,706)</b></p> <ul style="list-style-type: none"> <li>Imbalances in Bell's Palsy (4 vaccine; 0 placebo) and lymphadenopathy (64 vaccine, 6 placebo)</li> <li>6 deaths (2 vaccine; 4 placebo). None considered related to treatment</li> <li>4 related serious adverse events in vaccine recipients (shoulder injury, lymphadenopathy, ventricular arrhythmia, leg paresthesia)</li> </ul> |                            |

Abbreviations: AE = adverse event; GMC = geometric mean concentration; GMT = geometric mean titer; SAE = serious adverse event; VE = vaccine efficacy

## Appendix C – AZD1222 trials

| Study Design  | N    | Patient Selection  | Treatment Interventions  | Main results   |   |
|---|------|--|--|--|---|
|   |      |  |  | Immunogenicity   | Discontinuation and Safety  |
| <p>Folegatti PM et al.</p> <p>Replication deficient simian adenovirus vector</p> <p>AZD1222 (ChAdOx1 nCov-19)</p> <p>Phase 1/2 clinical trial</p> | 1077 | <p><b>Inclusion criteria</b></p> <ul style="list-style-type: none"> <li>18-55 y</li> <li>Healthy adults</li> </ul> <p><b>Exclusion criteria</b></p> <ul style="list-style-type: none"> <li>Hx of laboratory confirmed SARS-CoV-2 infection</li> <li>At higher risk for SARS-CoV-2 exposure (later amendment allowed for HCW with negative antibodies to be recruited)</li> <li>New onset fever, cough, SOB, anosmia, or ageusia</li> </ul> | <p><b>Intervention group</b></p> <p>ChAdOx1 nCoV-19 vaccine 5 X 10<sup>10</sup> VP in 0.5 mL administered intramuscularly</p> <ul style="list-style-type: none"> <li>Initial dose (n = 543)</li> <li>Booster dose after 28 d (n = 10)</li> <li>Prophylactic paracetamol (n = 56)</li> </ul> <p><b>Control group</b></p> <p>MenACWY (meningococcal) vaccine 0.5 mL administered intramuscularly (n = 534)</p> <ul style="list-style-type: none"> <li>Prophylactic paracetamol (n = 56)</li> </ul> | <p><b>Note:</b> Patients were divided into groups and not all received the same assessments.</p> <p><b>Spike-specific T cell response: IFN-gamma ELISpot response against SARS-CoV-2 peptides (Spot forming cells)</b></p> <ul style="list-style-type: none"> <li>Day 14: <ul style="list-style-type: none"> <li>ChAdOx1 Prime (n = 43): 856 [IQR:493.3, 1802]</li> <li>ChAdOx1 Prime-Boost (n = 10): 1642.3 [IQR: 1423.7, 2009.5]</li> <li>MenACWY (n = 44): 55.3 [48, 99.3]</li> </ul> </li> <li>Day 28: <ul style="list-style-type: none"> <li>ChAdOx1 Prime (n = 68): 554.3 [IQR: 311.3, 1017.7]</li> <li>ChAdOx1 Prime-Boost (n = 10): 528.7 [IQR: 376.3, 603]</li> <li>MenACWY (n = 69): 61.3 [48, 88]</li> </ul> </li> <li>Day 56: <ul style="list-style-type: none"> <li>ChAdOx1 Prime (n = 43): 424 [IQR: 221.3, 798.7]</li> <li>ChAdOx1 Prime-Boost (n = 10): 614 [IQR: 437.3, 666]</li> <li>MenACWY (n = 42): 66.7 [48, 123.3]</li> </ul> </li> </ul> <p><b>Anti-spike IgG using standardized ELISA (EU)</b></p> <ul style="list-style-type: none"> <li>Day 14: <ul style="list-style-type: none"> <li>ChAdOx1 Prime (n = 44): 102.7 [IQR:43.7, 186]</li> <li>ChAdOx1 Prime-Boost (n = 10): 137 [IQR: 46.4, 206.8]</li> <li>MenACWY (n = 44): 1 [1, 1]</li> </ul> </li> </ul> | <p><b>Note:</b> Patients were divided into groups and not all received the same assessments.</p> <ul style="list-style-type: none"> <li>No serious AEs reported.</li> <li>Local and systemic reactions were reported in the ChAdOx1 nCoV-19 group and were reduced in patients instructed/allowed to use paracetamol prophylactically (1 g every 6 h for 24 h) including pain, feeling feverish, chills, muscle ache, headache, and malaise.</li> <li>Immunogenicity in patients advised to take paracetamol prophylactically was similar to those who were not advised to do so; however, these data were not reported.</li> </ul> <p><b>Pain</b></p> <ul style="list-style-type: none"> <li>ChAdOx1 + paracetamol: n = 28 (50%)</li> <li>ChAdOx1: n = 328 (67%)</li> <li>MenACWY+ paracetamol: n = 18 (32%)</li> <li>MenACWY: n = 180 (38%)</li> </ul> <p><b>Tenderness</b></p> <ul style="list-style-type: none"> <li>ChAdOx1+ paracetamol: n =43 (77%)</li> <li>ChAdOx1: n = 403 (83%)</li> <li>MenACWY+ paracetamol: n = 26 (14%)</li> <li>MenACWY: n = 276 (58%)</li> </ul> <p><b>Chills</b></p> <ul style="list-style-type: none"> <li>ChAdOx1+ paracetamol: n = 15 (27%)</li> <li>ChAdOx1: n = 272 (56%)</li> <li>MenACWY: n = 5 (9%)</li> <li>MenACWY + paracetamol: n = 46 (10%)</li> </ul> <p><b>Fatigue</b></p> <ul style="list-style-type: none"> <li>ChAdOx1 + paracetamol: n = 40 (71%)</li> <li>ChAdOx1: n = 340 (70%)</li> <li>MenACWY+ paracetamol: n = 26 (46%)</li> <li>MenACWY I: n = 227 (48%)</li> </ul> <p><b>Headache</b></p> <ul style="list-style-type: none"> <li>ChAdOx1+ paracetamol: n = 24 (61%)</li> <li>ChAdOx1: n = 331 (68%)</li> <li>MenACWY+ paracetamol: n = 21 (37%)</li> <li>MenACWY: n = 195 (41%)</li> </ul> <p><b>Muscle ache</b></p> <ul style="list-style-type: none"> <li>ChAdOx1 + paracetamol: n = 27 (48%)</li> <li>ChAdOx1: n = 294 (60%)</li> <li>MenACWY+ paracetamol: n = 15 (26%)</li> <li>MenACWY: n = 118 (25%)</li> </ul> |

| Study Design | N | Patient Selection | Treatment Interventions | Main results  |   |
|--------------|---|-------------------|-------------------------|---|---|
|              |   |                   |                         | Immunogenicity  | Discontinuation and Safety  |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>• Day 28:               <ul style="list-style-type: none"> <li>◦ ChAdOx1 Prime (n = 127): 157.1 [IQR: 96.2, 316.9]</li> <li>◦ ChAdOx1 Prime-Boost (n = 10): 210.7 [IQR: 149.4, 321.6 9]</li> <li>◦ MenACWY (n = 130): 1 [1, 1]</li> </ul> </li> <li>• Day 56:               <ul style="list-style-type: none"> <li>◦ ChAdOx1 Prime (n = 43): 119 [IQR: 70.3, 203.4]</li> <li>◦ ChAdOx1 Prime-Boost (n = 10): 639.2 [IQR: 360, 792.2]</li> <li>◦ MenACWY (n = 44): 1 [1, 2.6]</li> </ul> </li> </ul> <p><b>Note:</b> EU values were obtained from CP and were not reported in text. However, ChAdOx1 Prime &amp; ChAdOx1 Prime-Boost responses at 14-56 d were visually within the range of values obtained from CP.</p> <p><b>Anti-SARS-CoV-2 neutralizing antibodies: PHE MNA<sub>80</sub></b></p> <ul style="list-style-type: none"> <li>• Day 28:               <ul style="list-style-type: none"> <li>◦ ChAdOx1 Prime (n = 35): 51 [IQR:32, 103]; <b>Note:</b> Neutralizing antibodies were detected in 32/35 (91%) with the PHE MNA<sub>80</sub> assay</li> <li>◦ ChAdOx1 Prime-Boost (n = 10): 70 [IQR: 32.8, 168]</li> <li>◦ MenACWY (n = 2): 10 [10, 10]</li> </ul> </li> </ul> <p><b>Anti-SARS-CoV-2 neutralizing antibodies: PHE PRNT<sub>50</sub></b></p> <ul style="list-style-type: none"> <li>• Day 28:</li> </ul> | <p><b>Malaise</b></p> <ul style="list-style-type: none"> <li>• ChAdOx1 + paracetamol: n = 27 (48%)</li> <li>• ChAdOx1: n = 296 (61%)</li> <li>• MenACWY+ paracetamol: n = 6 (11%)</li> <li>• MenACWY: n = 83 (17%)</li> </ul> |

| Study Design | N | Patient Selection | Treatment Interventions | Main results   |                            |
|--------------|---|-------------------|-------------------------|--|----------------------------|
|              |   |                   |                         | Immunogenicity   | Discontinuation and Safety |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>○ ChAdOx1 Prime (n = 35): 218 [IQR: 122, 395]; <b>Note:</b> Neutralizing antibodies were detected in 35/35 (100%) with the PHE PRNT<sub>50</sub> assay</li> <li>○ MenACWY (n = 2): 36.5 [30.8, 42.3]</li> </ul> |                            |

| Study Design  | N   | Patient Selection  | Treatment Interventions  | Main results  |  |
|---|-----|--|--|---|--|
|   |     |  |  | Immunogenicity  | Discontinuation and Safety   |
| <p>Ramasamy MN et al.</p> <p>Replication deficient simian adenovirus vector</p> <p><b>AZD1222 (ChAdOx1 nCov-19)</b></p> <p><b>Phase 2/3 clinical trial</b> (phase 2 interim results reported here)</p> <p><a href="#">NCT04400838</a></p> | 560 | For full inclusion and exclusion criteria, see <a href="#">NCT04400838</a> | <p><b>Intervention group</b></p> <p>Standard dose ChAdOx1 nCoV-19 vaccine 3.5-6.5 X 10<sup>10</sup> VP in 0.5 mL administered intramuscularly for 1 or 2 doses (separated by 28 d)</p> <p>Low dose ChAdOx1 nCoV-19 vaccine 2.2 X 10<sup>10</sup> VP in 0.22 or 0.5 mL administered intramuscularly for 1 or 2 doses (separated by 28 d)</p> <p><b>Control group</b></p> <p>MenACWY (meningococcal) vaccine 0.5 mL administered intramuscularly in 1 or 2 doses separated by 28 d</p> <p>Patients were stratified into 3 age groups</p> <ul style="list-style-type: none"> <li>• 18-55 y</li> <li>• 56-69 y</li> <li>• ≥ 70 y</li> </ul> <p>For the full break down of dosing groups with stratification, refer to interim trial <a href="#">publication</a> or <a href="#">NCT04400838</a></p> | <p><b>Spike-specific T cell response: IFN-gamma ELISpot response against SARS-CoV-2 peptides (Spot forming cells)</b></p> <p><b>18-55 yo (SD/SD):</b></p> <p>Day 14:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 two doses (n = 24): 1187 [IQR: 841, 2428]</li> </ul> <p>Day 28:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 two doses (n = 10): 292 [IQR: 178, 803]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 two doses (n = 23):413 [IQR: 245, 675]</li> </ul> <p><b>56-69 yo (LD/LD):</b></p> <p>Day 14:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 single dose (n = 30): 1001 [IQR:662, 1965]</li> <li>• ChAdOx1 two doses (n = 30): 1341 [IQR: 536, 2029]</li> </ul> <p>Day 28:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 single dose (n = 28): 511 [IQR:264, 790]</li> <li>• ChAdOx1 two doses (n = 29): 488 [IQR: 255,1043]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 two doses (n = 29): 501 [IQR: 253, 905]</li> </ul> <p><b>56-69 yo (SD/SD):</b></p> <p>Day 14:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 single dose (n = 21): 677 [IQR:411, 1503]</li> <li>• ChAdOx1 two doses (n = 29): 797 [IQR: 383, 1817]</li> </ul> <p>Day 28:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 single dose (n = 29): 335 [IQR: 162, 523]</li> <li>• ChAdOx1 two doses (n = 30): 591 [IQR: 238, 922]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>• ChAdOx1 two doses (n = 28): 798 [IQR: 462, 1186]</li> </ul> <p><b>≥ 70 yo (LD/LD):</b></p> <p>Day 14:</p> | <p>Thirteen serious ADEs were reported; none were attributed to the vaccine.</p> <p>The most common local ADEs were pain and tenderness at the injection site with the most common systemic ADEs of fatigue, headache, feverishness, and myalgia. Decreased reactogenicity was observed in older adults. Refer to pages 16-31 of the <a href="#">supplement</a> for details.</p> |



| Study Design | N | Patient Selection | Treatment Interventions | Main results  |                            |
|--------------|---|-------------------|-------------------------|---|----------------------------|
|              |   |                   |                         | Immunogenicity  | Discontinuation and Safety |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 49): 1009 [IQR:485, 2265]</li> <li>ChAdOx1 two doses (n = 44): 921 [IQR: 400, 1733]</li> </ul> <p>Day 28:</p> <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 47): 420 [IQR:232, 721]</li> <li>ChAdOx1 two doses (n = 43): 397 [IQR: 203, 715]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 43): 285 [IQR: 172, 554]</li> </ul> <p><b>≥ 70 yo (SD/SD):</b></p> <p>Day 14:</p> <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 48): 975 [IQR: 442, 1530]</li> <li>ChAdOx1 two doses (n = 48): 977 [IQR: 458, 1914]</li> </ul> <p>Day 28:</p> <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 47): 567 [IQR: 357, 1018]</li> <li>ChAdOx1 two doses (n = 49): 300 [IQR: 157, 492]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 47): 307 [IQR: 161, 516]</li> </ul> <p>Comparison across all three age groups in SD: <i>P</i> &lt; .0001</p> <p><b>SARS-CoV-2 micro-neutralization: PHE MNA<sub>80</sub></b></p> <p><b>18-55 yo (LD/LD):</b></p> <p>Day 28:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 45): 79 [IQR: 47, 127]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 41): 161 [IQR: 99, 233]</li> </ul> <p>Day 56:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 39):110 [IQR: 74, 184]</li> </ul> <p><b>18-55 yo (SD/SD):</b></p> <p>Day 28:</p> |                            |

| Study Design | N | Patient Selection | Treatment Interventions | Main results  |                            |
|--------------|---|-------------------|-------------------------|---|----------------------------|
|              |   |                   |                         | Immunogenicity  | Discontinuation and Safety |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 43): 47 [IQR: 5, 124]</li> </ul> Day 42: <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 39): 193 [IQR: 113, 238]</li> </ul> Day 56: <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 37): 185 [IQR: 129, 359]</li> </ul> <p><b>56-69 yo (LD/LD):</b></p> Day 28: <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 18): 64 [IQR: 41, 93]</li> <li>ChAdOx1 two doses (n = 21): 55 [IQR: 25, 79]</li> </ul> Day 42: <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 28): 143 [IQR: 79, 220]</li> </ul> Day 56: <ul style="list-style-type: none"> <li>ChAdOx1 one dose (n = 29): 45 [IQR: 27, 67]</li> <li>ChAdOx1 two doses (n = 27): 127 [IQR: 74, 183]</li> </ul> <p><b>56-69 yo (SD/SD):</b></p> Day 28: <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 9): 76 [IQR: 46, 179]</li> <li>ChAdOx1 two doses (n = 15): 72 [IQR: 35, 102]</li> </ul> Day 42: <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 20): 144 [IQR: 119, 347]</li> </ul> Day 56: <ul style="list-style-type: none"> <li>ChAdOx1 one dose (n = 10): 32 [IQR: 11, 63]</li> <li>ChAdOx1 two doses (n = 22): 178 [IQR: 124, 416]</li> </ul> <p><b>≥ 70 yo (LD/LD):</b></p> Day 28: <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 21): 47 [IQR: 23, 82]</li> <li>ChAdOx1 two doses (n = 34): 33 [IQR: 13, 65]</li> </ul> Day 42: |                            |

| Study Design | N | Patient Selection | Treatment Interventions | Main results   |                            |
|--------------|---|-------------------|-------------------------|--|----------------------------|
|              |   |                   |                         | Immunogenicity   | Discontinuation and Safety |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 34): 150 [IQR: 103, 255]</li> </ul> <p>Day 56:</p> <ul style="list-style-type: none"> <li>ChAdOx1 one dose (n = 20): 31 [IQR: 13, 84]</li> <li>ChAdOx1 two doses (n = 36): 111 [IQR: 61, 251]</li> </ul> <p><b>≥ 70 yo (SD/SD):</b></p> <p>Day 28:</p> <ul style="list-style-type: none"> <li>ChAdOx1 single dose (n = 49): 58 [IQR: 20, 120]</li> <li>ChAdOx1 two doses (n = 42): 48 [IQR: 21, 121]</li> </ul> <p>Day 42:</p> <ul style="list-style-type: none"> <li>ChAdOx1 two doses (n = 47): 161 [IQR: 73, 323]</li> </ul> <p>Day 56:</p> <ul style="list-style-type: none"> <li>ChAdOx1 one dose (n = 47): 44 [IQR: 22, 76]</li> <li>ChAdOx1 two doses (n = 43): 146 [IQR: 56, 239]</li> </ul> <p>Comparison across all age groups at day 42 in LD (<math>P = 0.899</math>) and SD (<math>P = .4</math>)</p> <p>Comparison between LD and SD at day 42:</p> <ul style="list-style-type: none"> <li>18-55yo: <math>P = .3287</math></li> <li>56-69yo: <math>P = .124</math></li> <li>≥70yo: <math>P = .6195</math></li> </ul> <p><b>Anti-spike IgG using standardized ELISA (EU)</b><br/>Refer to page 13 of <b>supplementary material</b> for detailed results</p> |                            |

| Study Design   | N      | Patient Selection   | Treatment Interventions  | Main results   |                            |
|--|--------|---|--|--|----------------------------|
|  |        |   |  | Immunogenicity   | Discontinuation and Safety |
| <b>Phase 3 trial</b><br><b>ChAdOx1 nCov-19 (AZD1222)</b><br><b>(NCT04516746)</b> | 30,000 | Inclusion <ul style="list-style-type: none"> <li>≥ 18 y</li> <li>Increased risk of SARS-CoV-2 infection</li> </ul> Exclusion <ul style="list-style-type: none"> <li>Confirmed or suspected immunosuppressive state</li> <li>Significant disease, disorder, or finding</li> <li>Prior or concomitant vaccine therapy for COVID-19</li> </ul> | Treatment <ul style="list-style-type: none"> <li>ChAdOx1 nCoV-19 vaccine <math>5 \times 10^{10}</math> vp (nominal <math>\pm 1.5 \times 10^{10}</math>) administered intramuscularly X 2 (separate doses by 4 wks)</li> </ul> Placebo <ul style="list-style-type: none"> <li>Saline intramuscularly X 2 (separate doses by 4 wks)</li> </ul> | Primary outcomes to be measured <ul style="list-style-type: none"> <li>First SARS-CoV-2 positive illness (by PCR) <math>\geq 15</math> d post second dose of study intervention</li> <li>AE incidence</li> <li>SAE incidence</li> <li>Local and systemic solicited AEs</li> </ul> Secondary outcomes to be measured <ul style="list-style-type: none"> <li>Asymptomatic infection measured by proportion of patients positive for SARS-CoV-2 nucleocapsid antibodies</li> <li>Symptomatic COVID-19 infection using CDC criteria</li> <li>University of Oxford defined symptomatic COVID-19</li> <li>Severe or critical symptomatic COVID-19</li> <li>Emergency department visits</li> <li>S antigen antibody response</li> <li>GMTs and GMFRs in SARS-CoV-2 neutralizing antibodies</li> </ul> |                            |

Abbreviations: AE = adverse events; CP = convalescent plasma; EU = elisa units; GMFR = geometric mean fold rise; GMT = geometric mean titers; IFN = interferon; LD = low dose; MNA = microneutralization assay; PRNT= Plaque reduction neutralization test; NAAT = nucleic acid amplification test; SAE = serious adverse event; SD = standard dose; VE = vaccine efficacy; VP: viral particles

## Appendix D – JNJ-78436735 trials

| Study Design | N   | Patient Selection  | Treatment Interventions  | Main results  |   |
|--------------|-----|--|--|---|---|
|              |     |  |  | Immunogenicity  | Discontinuation and Safety  |
| Phase 1/2a   | 796 | <p>For full inclusion and exclusion criteria, see <a href="#">NCT04436276</a></p> <p><b>Inclusion criteria</b></p> <ul style="list-style-type: none"> <li>Healthy patients ≥ 18-55 y</li> <li>Good or stable health patients ≥ 65 y</li> <li>BMI ≤ 30 kg/m<sup>2</sup></li> </ul> <p><b>Exclusion criteria</b></p> <ul style="list-style-type: none"> <li>Clinically significant acute illness</li> <li>Malignancy ≤ 5 y prior to screening (some exceptions)</li> <li>Neurological disorders</li> <li>Positive SARS-CoV-2 infection at screening</li> <li>Comorbidities associated with increased risk for progression to severe COVID-1</li> </ul> | <p><b>Treatment</b></p> <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp or 1X10<sup>11</sup> vp administered intramuscularly as a single dose or 2 doses separated by 8 wks</li> </ul> <p><b>Placebo</b></p> <ul style="list-style-type: none"> <li>Sodium chloride 0.9% 1 mL administered intramuscularly as a single dose or 2 doses separated by 8 wks<br/>Note: For single dose treatment arms, a second placebo dose was administered after 8 wks.</li> </ul> | <p>See <a href="#">preprint</a> for full description of cohorts and results.</p> <p>Humoral response by Spike-specific ELISA against SARS-CoV-2<br/><i>Cohort 1a (18-55 yo; 1 or 2 doses)</i></p> <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: EU/mL &lt;LLOQ in 94% of participants</li> <li>Day 29 GMT: 528 EU/mL (95% CI: 442, 630)</li> </ul> </li> <li>1X10<sup>11</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: EU/mL &lt;LLOQ in 98% of participants</li> <li>Day 29 GMT: 695 EU/mL (95% CI: 596, 810)</li> </ul> </li> <li>Observed in HCS: GMT: 899 EU/mL overlapping in the 95% CI of both above doses</li> </ul> <p><i>Cohort 3 (≥ 65yo; 1 or 2 doses [results are for the first 15 participants])</i></p> <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: EU/mL &lt;LLOQ</li> <li>Day 29 GMT: 507 EU/mL (95% CI: 181, 1418)</li> </ul> </li> <li>1X10<sup>11</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: EU/mL &lt;LLOQ</li> <li>Day 29 GMT: 248 EU/mL (95% CI: 122, 506)</li> </ul> </li> <li>Observed in HCS: GMT: 899 EU/mL overlapping in the 95% CI of both above doses</li> </ul> <p>Humoral response by neutralizing titers by wt/VNA (50% IC)<br/><i>Cohort 1a (18-55 yo; 1 or 2 doses; [results are for a subset n = 50 participants])</i></p> <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: &lt;LLOQ</li> <li>Day 29 GMT: 214 (95% CI: 177, 259)</li> </ul> </li> <li>1X10<sup>11</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: &lt;LLOQ</li> <li>Day 29 GMT: 243 (95% CI: 200, 295)</li> </ul> </li> <li>Observed in HCS: GMT: 522 overlapping in the 95% CI of both above doses</li> </ul> <p><i>Cohort 3 (≥65 yo; 1 or 2 doses; n = 375 [results are for the first 15 participants])</i></p> <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose <ul style="list-style-type: none"> <li>Baseline GMT: &lt;LLOQ</li> </ul> </li> </ul> | <p>Solicited Local AE</p> <ul style="list-style-type: none"> <li>Cohort 1: 58%</li> <li>Cohort 3: 27%</li> <li>Most frequent local AE was injection site pain</li> </ul> <p>SAEs</p> <ul style="list-style-type: none"> <li>Cohort 1: <ul style="list-style-type: none"> <li>Total: 64%</li> <li>Fever: 19%</li> <li>Grade 3 fever: 5%</li> </ul> </li> <li>Cohort 3: <ul style="list-style-type: none"> <li>Total: 36%</li> <li>Fever: 4%</li> <li>Grade 3 fever: 0%</li> </ul> </li> <li>Most frequent SAEs were headache, fatigue, and myalgia</li> </ul> <p>Unsolicited AE</p> <ul style="list-style-type: none"> <li>Cohort 1a: 12 reported; 8 deemed related to treatment including WBC increase, malaise, back pain, hypotensive crisis, insomnia, fever, and lightheadedness; 1 necessitating drug withdrawal (pyrexia)</li> <li>Cohort 3: 6 reported; 4 deemed related to treatment including: systolic hypertension, hypertension, vomiting, and dizziness</li> </ul> <p>Assessing risk for VAERD: CD4+ Th1 &amp; Th2 responses<br/><i>Cohort 1a Th1 responses</i></p> <ul style="list-style-type: none"> <li>Baseline: undetectable</li> <li>15 days post vaccination <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose: 0.08% (95% CI: 0.05, 0.16)</li> <li>1X10<sup>11</sup> vp dose: 0.11% (95% CI: 0.07, 0.16)</li> </ul> </li> </ul> <p><i>Cohort 3 (first participants) Th1 responses</i></p> <ul style="list-style-type: none"> <li>Baseline: undetectable</li> <li>15 days post vaccination <ul style="list-style-type: none"> <li>5X10<sup>10</sup> vp dose: 0.36% (95% CI: 0.15, 0.89)</li> </ul> </li> </ul> |

| Study Design | N | Patient Selection | Treatment Interventions | Main results   |  |
|--------------|---|-------------------|-------------------------|--|--|
|              |   |                   |                         | Immunogenicity   | Discontinuation and Safety   |
|              |   |                   |                         | <ul style="list-style-type: none"> <li>○ Day 29 GMT: 196 (95% CI: 69, 560)</li> <li>● 1X10<sup>11</sup> vp dose <ul style="list-style-type: none"> <li>○ Baseline GMT: &lt;LLOQ</li> <li>○ Day 29 GMT: 127 (95% CI: &lt;LLOQ, 327)</li> </ul> </li> <li>● Observed in HCS: GMT: 522 overlapping in the 95% CI of both above doses</li> </ul> <p>Cellular response by Th1 cytokine producing CD4+ Tcell (S-specific)</p> <p><i>Cohort 1a (subset)</i></p> <ul style="list-style-type: none"> <li>● Positive response on day 14: 80%</li> </ul> <p><i>Cohort 3 (subset)</i></p> <ul style="list-style-type: none"> <li>● Positive response on day 14: 83%</li> </ul> <p>Cellular response by CD8+ Tcell (S-specific)</p> <p><i>Cohort 1a</i></p> <ul style="list-style-type: none"> <li>● Positive response <ul style="list-style-type: none"> <li>○ 5X10<sup>10</sup> vp dose: 51% (95% CI: 39, 63)</li> <li>○ 1X10<sup>11</sup> vp dose: 64% (95% CI: 52, 75)</li> </ul> </li> <li>● Response magnitude 15 days post vaccination <ul style="list-style-type: none"> <li>○ 5X10<sup>10</sup> vp dose: 0.07% (95% CI: 0.03, 0.19)</li> <li>○ 1X10<sup>11</sup> vp dose: 0.09% (95% CI: 0.05, 0.19)</li> </ul> </li> </ul> <p><i>Cohort 3 (first participants)</i></p> <ul style="list-style-type: none"> <li>● Positive response <ul style="list-style-type: none"> <li>○ 5X10<sup>10</sup> vp dose &amp; 1X10<sup>11</sup> vp dose: 33% (95% CI: 4, 78)</li> </ul> </li> <li>● Response magnitude 15 days post vaccination <ul style="list-style-type: none"> <li>○ 5X10<sup>10</sup> vp dose: 0.05% (95% CI: 0.02, 0.24)</li> <li>○ 1X10<sup>11</sup> vp dose: 0.07% (95% CI: 0.02, 0.14)</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>○ 1X10<sup>11</sup> vp dose: 0.13% (95% CI: 0.04, 0.5)</li> </ul> <p><i>Th2 responses</i></p> <ul style="list-style-type: none"> <li>● One patient in cohort 1a 5X10<sup>10</sup> group exhibited a response and the Th1/Th2 ratio was 28.9, indicative of a Th1-skewed response</li> </ul> <p><i>Th1/Th2 ratio (all)</i></p> <ul style="list-style-type: none"> <li>● Range: 1-68.5</li> </ul> |

| Study Design   | N      | Patient Selection   | Treatment Interventions  | Main results   |                            |
|--|--------|---|--|--|----------------------------|
|  |        |   |  | Immunogenicity   | Discontinuation and Safety |
| Phase 3 trial<br>Ad26.COV2.S<br>(JNJ-78436735)<br>ENSEMBLE   | 40,000 | For full inclusion and exclusion criteria, see <a href="#">NCT04505722</a><br><br>Inclusion<br>• ≥ 18 y | Treatment<br>• 5X10 <sup>10</sup> vp administered intramuscularly X 1<br><br>Placebo<br>• Placebo administered intramuscularly X 1                         | Primary outcomes to be measured<br>• Molecularly confirmed moderate to severe COVID-19 (onset at least 14 d post vaccination) in SARS-CoV-2 seronegative adults<br><br>Secondary outcomes to be measured<br>• Molecularly confirmed moderate to severe COVID-19 (day 2-end of study) regardless of serostatus<br>• Molecularly confirmed moderate to severe COVID-19 (onset at least 14 d post vaccination through end of study) regardless of serostatus<br>• Molecularly confirmed moderate to severe COVID-19 (day 2-end of study)<br>• Patients requiring medication intervention (i.e. hospitalization, ICU admission, mechanical ventilation, ECMO)<br>• SARS-CoV-2 viral load<br>• Molecularly confirmed mild COVID-19<br>• Molecularly confirmed COVID-19 by FDA harmonized case definition<br>• Burden of disease based on first occurrence of confirmed symptomatic COVID-19<br>• Serologic conversion by ELISA<br>• Occurrence of SARS-CoV-2 infection<br>• SAE<br>• Medically attended AE<br>• Medically attended AE leading to study discontinuation<br>• Solicited local AE<br>• Solicited systemic AE<br>• Unsolicited local AE<br>• SARS-CoV-2 neutralizing antibody titers<br>• SARS-CoV-2 binding antibodies |                            |
| Phase 3 trial<br>Ad26.COV2.S<br>(JNJ-78436735)<br>ENSEMBLE 2 | 30,000 | For full inclusion and exclusion criteria, see <a href="#">NCT04614948</a><br><br>Inclusion<br>• ≥ 18 y | Treatment<br>• Vaccine administered intramuscularly X 2, separated by 57 d<br><br>Placebo<br>• Placebo administered intramuscularly X 2, separated by 57 d | Primary outcomes to be measured<br>• Number of participants with first occurrence of molecularly confirmed moderate to severe/critical COVID-19 and who were seronegative at baseline  |                            |

Abbreviations: AE = adverse events; CP = convalescent plasma; ECMO = extracorporeal membrane oxygenation; EU = elisa units; IC = inhibitory concentration; HCS = human convalescent serum; ICS = intracellular cytokine staining; IFN= interferon; LLOQ = lower limit of quantification; MNA = microneutralization assay; PRNT= Plaque reduction neutralization test; NAAT = nucleic acid amplification test; SAE = serious adverse event; VAERD = vaccine associated enhanced respiratory disease; VE = vaccine efficacy; VP: viral particles; wtVNA = wild type virus neutralization assay


## Appendix E – NVX-CoV2373 trials

| Study Design  | N   | Patient Selection   | Treatment Interventions  | Main results  |   |
|---|-----|---|--|---|---|
|   |     |   |  | Immunogenicity  | Discontinuation and Safety  |
| <p><b>Keech C, et al.</b></p> <p>SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</p> <p>Randomized, placebo-controlled, phase 1/2 trial (<i>only phase 1 results reported here</i>)</p> | 134 | <p>Healthy adults 18 to 59 y</p> <p>For inclusion/exclusion criteria, see <b>NCT04368988</b></p> <p>Baseline characteristics</p> <ul style="list-style-type: none"> <li>Male, n = 66 (50.4%)</li> <li>Age, mean (SD): 30.8 y (10.2)</li> <li>White, n = 103 (78.6%)</li> <li>Hispanic or Latino, n = 19 (14.5%)</li> <li>Asian, n = 17 (13.0%)</li> <li>AI or AN, n = 7 (5.3%)</li> <li>Black or AA, n = 2 (1.5%)</li> <li>BMI, mean (SD): 25.19 (3.672)</li> </ul> | <p><b>Intervention groups</b></p> <p>2 injections, 21 d apart:<br/>rSARS-CoV-2 (5 or 25 mcg) ± adjuvant (Matrix-M1) and/or placebo</p> <ul style="list-style-type: none"> <li>Group A: Placebo x 2 (n = 23)</li> <li>Group B: 25 mcg x 2 (n = 25)</li> <li>Group C: 5 mcg + Matrix-M1 x 2 (n = 29*)</li> <li>Group D: 25 mcg + Matrix-M1 x 2 (n = 28*)</li> <li>Group E: 25 mcg + Matrix-M1 (dose 1) then Placebo (Dose 2) (n = 26)</li> </ul> <p>*Including 3 "sentinels", which were individuals administered vaccine as part of an initial open-label investigation to assess reactogenicity, prior to 1:1:1:1:1 randomization</p> <p><b>Control group</b></p> <p>Convalescent serum samples</p> <ul style="list-style-type: none"> <li>GMT IgG (n = 29)</li> <li>GMT neutralizing antibody (n = 32)</li> </ul> | <p><b>GMT (95% CI) IgG responses (reported in EU/mL) to rSARS-CoV-2 at day 28:</b></p> <ul style="list-style-type: none"> <li>Group A: 110.6 (89.7, 136.3)</li> <li>Group B: 206.9 (138.9, 308.1)</li> <li><b>Group C: 15318.8 (9486.8, 24736.0)</b></li> <li><b>Group D: 20429.2 (11974.4, 34853.6)</b></li> <li>Group E: 3503.2 (2378.4, 5160.1)</li> <li><b>Convalescent serum: 8343.7 (4420.9, 15747.5)</b></li> </ul> <p><b>GMT (95% CI) IgG responses (reported in EU/mL) to rSARS-CoV-2 at day 35:</b></p> <ul style="list-style-type: none"> <li>Group A: 113.5 (93.6, 137.6)</li> <li>Group B: 575.5 (331.7, 998.5)</li> <li><b>Group C: 63160.4 (47117.3, 84666.0)</b></li> <li><b>Group D: 47521.0 (33803.7, 66804.6)</b></li> <li>Group E: 2932.0 (1987.7, 4324.8)</li> <li><b>Convalescent serum: 8343.7 (4420.9, 15747.5)</b></li> </ul> <p><b>GMT (95% CI) neutralizing antibody responses (MN IC<sub>&gt;99%</sub>) to rSARS-CoV-2 at day 21:</b></p> <ul style="list-style-type: none"> <li>Group A: 20.0 (20.0, 20.0)</li> <li>Group B: 21.7 (19.2, 24.6)</li> <li><b>Group C: 103.3 (74.8, 142.6)</b></li> <li><b>Group D: 126.2 (79.5, 200.4)</b></li> <li>Group E: 117.8 (74.2, 187.0)</li> <li><b>Convalescent serum: 983.8 (579.4,1670.5)</b></li> </ul> <p><b>GMT (95% CI) neutralizing antibody responses (MN IC<sub>&gt;99%</sub>) to rSARS-CoV-2 at day 35:</b></p> <ul style="list-style-type: none"> <li>Group A: 20.0 (20.0, 20.0)</li> <li>Group B: 41.4 (27.5, 62.4)</li> <li><b>Group C: 3906.3 (2555.9, 5970.0)</b></li> <li><b>Group D: 3305.0 (2205.3, 4953.2)</b></li> <li>Group E: 127.6 (81.8, 199.1)</li> <li><b>Convalescent serum: 983.8 (579.4,1670.5)</b></li> </ul> <p><b>SARS-CoV-2 T-cell responses</b></p> <ul style="list-style-type: none"> <li>T-cell responses investigated in 16 participants randomly selected from groups A-D</li> </ul> | <p>Discontinuations due to safety (n = 1)</p> <ul style="list-style-type: none"> <li>25 mcg + Matrix-M1 group – second vaccine in series not received due to unsolicited AE (mild cellulitis associated unrelated IV placement)</li> </ul> <p>Local and systemic reactogenicity was <u>absent or mild</u> in majority of participants* after first vaccination</p> <ul style="list-style-type: none"> <li>Local: 100%, 96%, 89%, 84%, and 88% of participants in groups A, B, C, D, and E, respectively</li> <li>Systemic: 91%, 92%, 96%, 68%, and 89%</li> <li>2 participants (1 each in groups D and E) had severe AE (headache, fever, and malaise)</li> </ul> <p>Local and systemic reactogenicity was <u>absent or mild</u> in majority of participants* after 2<sup>nd</sup> vaccination</p> <ul style="list-style-type: none"> <li>Local: 100%, 100%, 65%, 67%, and 100%</li> <li>Systemic: 86%, 84%, 73%, 58%, and 96%</li> <li>1 participant in group D had a severe local event (tenderness) and 8 participants (1-2 in each group) had severe systemic events (most commonly joint pain and fatigue)</li> <li>1 participant in group D had fever, and only on day 1</li> </ul> <p>Lab values (serum chemistry and hematology) assessed at days 7 and 28, according to FDA toxicity scoring.</p> <ul style="list-style-type: none"> <li>13 participants (10%) experienced lab abnormalities of grade 2 or higher</li> </ul> |



| Study Design   | N   | Patient Selection                | Treatment Interventions   | Main results   |  |
|--|---|----------------------------------|---|--|--|
|  |   |                                  |   | Immunogenicity   | Discontinuation and Safety   |
|  |   |                                  |   | <ul style="list-style-type: none"> <li>Adjuvanted regimens were shown to induce antigen-specific polyfunctional CD4+ T-cell responses, with a "strong bias" toward Th1 phenotype and minimal Th2 responses</li> </ul>  | <ul style="list-style-type: none"> <li>Not associated with any clinical manifestations; no worsening with repeat vaccination</li> <li>N = 6 had transient reductions in Hgb from baseline with resolution within 7-21 d</li> <li>N = 4 (including n = 1 who received placebo) had elevated LFTs that resolved in 7-14 d (prior to second vaccination)</li> </ul> |
| <p>Phase 3 trial – ongoing</p> <p>Randomized, placebo-controlled, observer-blinded study</p> | <p>5,500 enrolled in UK</p> <p>Up to 15,000</p> <p>Event-driven, final number will depend on number of events</p> | <p>Healthy adults 18 to 84 y</p> | <p>Intervention</p> <ul style="list-style-type: none"> <li>5 mcg NVX-CoV2373 + 50 mcg Matrix-M injection given on Day 1 and on Day 21</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>Placebo – 0.9% sodium chloride injection</li> </ul> <p>Up to 400 participants will also receive a licensed seasonal influenza vaccine as part of a co-administration sub-study</p> | <p>The primary efficacy analysis will be an event-driven analysis based on the number of participants with symptomatic or moderate to severe COVID-19. An interim analysis will be performed when 67% of the desired number of cases is reached.</p> <p>There will be 2 primary endpoints:</p> <ul style="list-style-type: none"> <li>First occurrence of PCR-confirmed, <b>symptomatic COVID-19</b> with onset at least 7 d after the second dose in volunteers not previously infected with SARS-CoV-2</li> <li>First occurrence of PCR-confirmed, <b>symptomatic moderate or severe COVID-19</b> with onset at least 7 d after the second dose in volunteers not previously infected with SARS-CoV-2</li> </ul> |  |

Abbreviations: AA = African American; AE = adverse events; AI = American Indian; AN = Alaska Native; BMI = body-mass index; ELISA = enzyme-linked immunosorbent assay; GMEUs = geometric mean ELISA units; GMT = geometric mean titer; MN IC<sub>>99%</sub> = microneutralization assay with an inhibitory concentration >99%; VE = vaccine efficacy; rSARS-CoV-2 = recombinant severe acute respiratory syndrome coronavirus 2



Vizient, Inc.  
290 E. John Carpenter Freeway  
Irving, TX 75062-5146  
(800) 842-5146